1. Executive Background & Scope of Evidence

1.1 Botanical, Ethnopharmacological, and Therapeutic Profile

Curcuma longa L. (turmeric) is a perennial botanical species belonging to the Zingiberaceae (ginger) family. Asian ethnopharmacological traditions have long used its rhizomes, notably in Traditional Chinese Medicine (TCM) and Ayurveda. In TCM, turmeric is recognized for its capacity to invigorate blood circulation and resolve blood stasis. Modern cellular and clinical evaluations confirm that its primary bioactive polyphenol is curcumin, a natural compound exhibiting a broad multi-target therapeutic profile:

• Anti-Inflammatory Properties: Suppresses key enzymatic signaling cascades and pro-inflammatory cytokine networks.

• Antitumor and Chemopreventive Activity: Regulates signal transduction pathways involved in cell proliferation, apoptosis, angiogenesis, and malignant transformation.

• Antioxidant Properties: Neutralizes reactive oxygen species (ROS) and mitigates tissue biomarkers of oxidative stress.

• Lipid-Regulating Activity: Modulates systemic lipid profiles and metabolic parameters.

• Anticoagulant Effects: Influences vascular stasis, platelet aggregation, and hematological dynamics.

In oral mucosal pathology, curcumin has attracted clinical interest for managing oral lichen planus (OLP). OLP is a chronic immunological disease of the oral mucosa classified as an oral potentially malignant disorder (OPMD), with a documented malignant transformation rate of 1.14% (95% CI: 0.84–1.49%).

1.2 Scope of Meta-Analytic Evidence Base

This synthesis report integrates meta-analytic evidence evaluating oral and topical curcumin formulations across two clinical domains: degenerative joint disease (Knee Osteoarthritis) and chronic mucosal inflammation (oral lichen planus).

Note: Comparative mapping of foundational meta-analytic frameworks evaluating curcumin formulations in joint degradation and mucosal pathology.

2. Preclinical & Molecular Mechanisms of Action

2.1 Anti-Inflammatory, Enzymatic, and Neurotransmitter Regulation

Curcumin suppresses tissue-damaging inflammatory processes by modulating upstream transcriptional signaling pathways. Preclinical models show that curcumin blocks activation of Nuclear Factor-kappa B (NF-κB) and the Toll-like Receptor 4/MyD88 (TLR4/MyD88) cascade. Downstream of these transcriptional regulators, curcumin directly inhibits the expression and biological activity of primary inflammatory enzymes:

• Cyclooxygenase-2 (COX-2)

• Lipoxygenase

• Inducible Nitric Oxide Synthase (iNOS)

Inhibition of these enzymatic drivers reduces the mRNA expression and cellular secretion of critical pro-inflammatory cytokines, chemokines, and inflammatory mediators:

• Interleukin-1β (IL-1β)

• Interleukin-6 (IL-6)

• Interleukin-8 (IL-8)

• Tumor Necrosis Factor-α (TNF-α)

• Prostaglandin E2 (PGE2)

• Nitric Oxide (NO)

2.2 Chondroprotective and Extracellular Matrix Degradation Mechanisms

In articular joint cartilage, pro-inflammatory cytokines such as IL-1β and TNF-α induce matrix degradation, leading to progressive cartilage loss. Curcumin preserves cartilage structural integrity by suppressing cytokine-induced inflammatory pathways in chondrocytes.

Key chondroprotective cellular mechanisms include:

• Suppression of Matrix Metalloproteinases: Curcumin directly inhibits IL-1β- and TNF-α-stimulated expression of MMP-1, MMP-3, and MMP-9, halting the enzymatic cleavage of type II collagen and proteoglycan components within the extracellular matrix.

• Chondrocyte Homeostasis: Curcumin promotes chondrocyte proliferation and suppresses chondrocyte apoptosis under catabolic conditions.

• Up-regulation of Protective Regulators: Curcumin increases the expression of CITED2 (CBP/p300-interacting transactivator with ED-rich tail 2), a transcriptional regulator that counters matrix degradation and maintains cartilage homeostasis.

3. Clinical Efficacy in Oral Potentially Malignant & Inflammatory Mucosal Disorders (OLP Analysis)

3.1 Comparative Pain and Burning Sensation Reduction

Meta-analyses of clinical trials comparing curcumin with active corticosteroid controls (topical triamcinolone acetonide 0.1%, betamethasone, or systemic prednisone) show rapid analgesic onset and sustained symptom relief.

Time-course pooled standardized mean differences (SMD) for pain and burning severity (measured via Visual Analog Scale [VAS] or Numerical Rating Scale [NRS]) demonstrate:

• 1 Week Follow-Up: Curcumin achieved significantly superior pain reduction compared to corticosteroid controls (SMD = -0.70, 95% CI: -1.33 to -0.07, p = 0.03).

• 2 Weeks Follow-Up: Curcumin demonstrated equivalent analgesic efficacy to corticosteroids (SMD = -0.23, 95% CI: -0.75 to 0.29).

• 4-Week Follow-Up: Analgesic suppression remained comparable between groups (SMD = 0.21, 95% CI: -0.06 to 0.47).

• 12-Week Follow-Up: Long-term symptom control did not differ significantly between interventions (SMD = 0.33, 95% CI: -0.05 to 0.72).

Delivery vehicles and administration schedules influence early symptom response. Topical preparations (1% gel, 5% oral paste) applied more frequently (e.g., 6 times daily vs. 3 times daily) and systemic formulations (oral nanocurcumin 80 mg capsules) increase mucosal contact time or systemic absorption, contributing to rapid early symptom reduction.

3.2 Objective Clinical Improvement and Lesion Resolution

Objective clinical signs—evaluated using the Thongprasom Sign Score (TSS), Modified Oral Mucositis Index (MOMI), and direct planimetric measurements of erosion, ulceration, and erythema—show that curcumin achieves lesion resolution equivalent to corticosteroid therapy across evaluated time points (p > 0.05).

Individual trial analyses highlight specific advantages across mucosal parameters:

• Erythema Reduction: Clinical trials by Keshari et al. (p = 0.002), Pai & Ganesan (p = 0.02), and Singh et al. showed that topical curcumin reduced mucosal erythema scores significantly more than topical triamcinolone acetonide 0.1%.

• Burning Sensation Resolution: Pai & Ganesan noted significantly greater suppression of burning sensation in the curcumin group relative to corticosteroids (p = 0.001).

Higher application frequencies (e.g., 1% gel applied 6 times daily) and bio-enhanced delivery vehicles overcome rapid salivary clearance, maintaining effective local tissue concentrations required for lesion resolution.

4. Clinical Efficacy in Degenerative Joint Disorders (KOA Network Meta-Analysis)

4.1 Pain Relief Metrics (VAS Pain Score Analysis)

In the Bayesian network meta-analysis of 23 RCTs involving 2,175 knee osteoarthritis patients, 9 trials evaluated changes in Visual Analog Scale (VAS) pain scores across 6 intervention categories. Curcumin monotherapy demonstrated statistically significant pain reduction compared to placebo:

• Curcumin vs. Placebo: Mean Difference (MD) = -1.63 (95% CI: -2.91 to -0.45).

4.2 Functional Restoration and WOMAC Subscale Analysis

Across Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) endpoints, curcumin yielded improvements in functional mobility and overall joint performance:

• Total WOMAC Score (9 RCTs): Curcumin monotherapy was statistically superior to placebo (MD = -18.85, 95% CI: -29.53 to -8.76).

• WOMAC Pain Subscale (8 RCTs): Curcumin monotherapy significantly reduced joint pain scores relative to placebo (MD = -2.24, 95% CI: -4.57 to -0.52).

• WOMAC Physical Function (PF) Subscale (7 RCTs): Pairwise differences between active pharmacotherapies were not statistically significant; however, probability rankings identified curcumin as the top single intervention for physical function restoration.

• WOMAC Joint Stiffness Subscale (7 RCTs): Pairwise comparisons showed no statistically significant differences between active agents, with curcumin and conventional NSAIDs showing efficacy comparable to placebo.

4.3 Rescue Medication (RM) Sparing Effect

Analysis of 11 RCTs reporting rescue medication (e.g., acetaminophen, ibuprofen) reliance demonstrated that curcumin-containing regimens significantly reduce the consumption of add-on analgesics relative to placebo:

• Curcumin Monotherapy vs. Placebo: Odds Ratio (OR) = 0.17 (95% CI: 0.08 to 0.36)

• NSAIDs Monotherapy vs. Placebo: OR = 0.11 (95% CI: 0.02 to 0.47)

• Curcumin + NSAIDs Combination vs. Placebo: OR = 0.01 (95% CI: 0.00 to 0.13)

• Curcumin + NSAIDs Combination vs. NSAIDs Alone: OR = 0.09 (95% CI: 0.01 to 0.76)

Combining curcumin with synthetic NSAIDs produces a synergistic sparing effect, significantly reducing total pharmaceutical analgesic consumption compared to NSAID monotherapy.

5. Comparative SUCRA Probability Rankings & Treatment Optimization

5.1 SUCRA Cumulative Ranking Metrics

The Surface Under the Cumulative Ranking Curve (SUCRA) quantifies the overall probability that each intervention ranks as the most effective or safest choice across the evaluated endpoints.

Note: SUCRA (Surface Under the Cumulative Ranking Curve) percentages represent cumulative ranking probabilities. Higher percentages indicate greater comparative efficacy for therapeutic outcomes and a lower incidence of adverse reactions for safety outcomes.

5.2 Clinical Prescription Insights

• Primary Analgesia & Functional Recovery: Curcumin monotherapy ranks highest across SUCRA metrics for reducing VAS pain (80.71%), Total WOMAC scores (78.79%), WOMAC Pain (75.96%), and WOMAC Physical Function (75.88%), supporting its role as a standalone option for symptom management and functional recovery.

• Optimized Sparing Regimens: The Curcumin + NSAIDs combination ranks highest for minimizing rescue medication use (98.91%) while showing a favorable safety rank for adverse drug events (79.46%). This dual profile allows lower synthetic NSAID dosages without compromising analgesic efficacy.

6. Safety, Bioavailability Formulations, and Risk of Bias Analysis

6.1 Safety Profile and Adverse Event (AE) Comparative Analysis

• Knee Osteoarthritis Safety Profile: Network meta-analysis of 20 RCTs evaluating safety demonstrated that curcumin-containing regimens significantly reduce adverse drug reactions relative to conventional synthetic NSAIDs:

  • Curcumin Monotherapy vs. NSAIDs Alone: OR = 0.51 (95% CI: 0.25 to 0.94), showing a lower rate of adverse events.

  • Curcumin + NSAIDs Combination vs. NSAIDs Alone: OR = 0.23 (95% CI: 0.06 to 0.90), indicating a lower rate of adverse reactions.

  • NSAIDs Monotherapy Risk: Synthetic NSAID monotherapy exhibited the lowest safety probability among evaluated active treatments (SUCRA = 8.19%).

• Oral Lichen Planus Safety Profile: Corticosteroid therapy was associated with localized adverse effects, including oral candidiasis, xerostomia, mucosal thinning, and burning sensations. Curcumin formulations were well tolerated across trials, with zero to minimal self-limiting side effects (e.g., mild transient burning or local irritation that resolved within the first week).

6.2 Bioavailability Formulations and Administration Regimens

To overcome the natural lipophilicity, rapid systemic elimination, and low intrinsic oral bioavailability of native curcuminoids, multiple bio-optimized commercial formulations were utilized across the clinical trial base:

• Longvida®: Solid lipid curcumin particles (80 mg curcumin per capsule).

• CuraMed®: Curcuminoid complex extract (333 mg curcuminoids per capsule).

• SinaCurcumin™: Soft gelatin capsules containing nanomicelles (40 mg curcuminoids) to enhance systemic absorption.

• FLEXOFYTOL®: Bio-optimized Curcuma longa extract (46.67 mg extract per capsule).

• BCM-95® (Biocurcumax): Standardized extract combining curcuminoids with essential oils of turmeric (≥95% total complex, ≥88% curcuminoids, ≥68% curcumin).

• Theracurmin®: Highly bioavailable submicronized curcumin dispersion (180 mg curcumin).

• CurQfen®: Curcumagalactomannoside (CGM) complex combining curcuminoids with soluble fenugreek dietary fiber.

• Curcugen®: Water-dispersible formulation containing 50% curcuminoids.

• Turmacin™ (NR-INF-02): Water-soluble aqueous extract rich in turmerosaccharides.

Administration Frequency Impact: In topical OLP management, applying 1% curcumin gel 6 times daily reduced clinical sign scores and pain severity more than a 3-times-daily regimen (Thomas et al.), indicating that adequate mucosal application frequency is essential for optimal therapeutic response.

6.3 Methodological Quality, Risk of Bias, and Trial Limitations

Methodological Quality Summary

• OLP Evidence Base: Quality evaluation via the Cochrane RoB 2 tool identified 1 trial at “Low Risk” of bias (Kia et al. 2020). The remaining 10 trials presented either “High Risk” (7 trials: Nosratzehi et al. 2018; Tantia & Gupta 2021; Thomas et al. 2017; Keshari et al. 2015; Patel et al. 2022; Singh et al. 2021; Kotb et al. 2025) or “Some Concerns” (3 trials: Kia et al. 2015; Biswas et al. 2018; Pai & Ganesan 2018), primarily due to incomplete descriptions of randomization sequences, inadequate blinding, and selective outcome reporting.

• KOA Evidence Base: Assessment of 23 RCTs demonstrated overall acceptable methodology, with low risk in random allocation generation across 21 RCTs. However, 4 trials had high risk due to unblinded designs, and the funnel plot showed asymmetry for VAS pain and total WOMAC endpoints, suggesting small-sample effects or publication bias.

Clinical Trial Limitations

1. Patient Population Heterogeneity: KOA trials included patients across Kellgren-Lawrence grades 1-4 without subgroup stratification, obscuring stage-specific treatment responsiveness.

2. Product Standardization & Purity: Heterogeneous extraction protocols, excipient compositions, and active concentration variations across commercial preparations complicate direct cross-study comparisons.

3. Limited Direct Active-Comparator Arms: Few trials directly compared curcumin against chondroprotective agents (CP) or direct combination therapies (Curcumin + NSAIDs).

4. Inconsistent Diagnostic Verification: Several OLP clinical trials relied exclusively on clinical examination without mandatory histopathological confirmation.

Recommendations for Future Clinical Trial Designs

1. Mandatory Disease-Stage Subgroup Stratification: Design future KOA trials around explicit Kellgren-Lawrence structural severity grades (e.g., K-L Grade 2 vs. Grade 4) to define specific therapeutic windows.

2. Standardized Dosing & Bioavailability Protocols: Utilize bio-enhanced delivery systems with validated pharmacokinetic profiles and standardized dosage metrics.

3. Extended Diagnostic & Follow-Up Windows: Incorporate mandatory histopathological confirmation for mucosal lesion trials and establish long-term follow-up periods (>6–12 months) to assess recurrence rates and disease modification.

References

1. Al-Maweri, S. A., Al-Qadhi, G., Alqutaibi, A. Y., Sallam, N. M., Assad, M., Abdulghani, M. A., & Mohammed, M. M. A. (2025). Curcumin versus corticosteroids for symptomatic oral lichen planus: A systematic review and meta-analysis. Clinical and Experimental Dental Research, 11(5), Article e70227. (Source: Clinical Exp Dental Res - 2025 - Al‐Maweri - Curcumin Versus Corticosteroids for Symptomatic Oral Lichen Planus A.pdf)

2. Cleveland Clinic Health Essentials. (2022). 6 health benefits of turmeric. (Source: Turmeric Health Benefits and Side Effects.pdf)

3. Hewlings, S. J., & Kalman, D. S. (2017). Curcumin: A review of its effects on human health. Foods, 6(10), Article 92. (Sources: foods-06-00092.pdf & foods-06-00092-v3.pdf)

4. Johns Hopkins Medicine. (2026). Turmeric benefits. Johns Hopkins Health Library. (Source: Turmeric Benefits _ Johns Hopkins Medicine.pdf)

5. Kou, H., Huang, L., Jin, M., He, Q., Zhang, R., & Ma, J. (2023). Effect of curcumin on rheumatoid arthritis: A systematic review and meta-analysis. Frontiers in Immunology, 14, Article 1121655. (Source: fimmu-14-1121655.pdf)

6. Liu, X., Lin, L., & Hu, G. (2024). Meta-analysis of the effect of curcumin supplementation on skeletal muscle damage status. PLoS ONE, 19(7), Article e0299135. (Source: journal.pone.0299135.pdf)

7. Memorial Sloan Kettering Cancer Center. (2026). The truth about turmeric and cancer. (Source: The Truth About Turmeric and Cancer _ Memorial Sloan Kettering Cancer Center.pdf)

8. Mokgalaboni, K., Mashaba, R. G., Phoswa, W. N., & Lebelo, S. L. (2024). Curcumin attenuates hyperglycemia and inflammation in type 2 diabetes mellitus: Quantitative analysis of randomized controlled trial. Nutrients, 16(23), Article 4177. (Source: nutrients-16-04177-v4.pdf)

9. National Cancer Institute. (2023). PDQ® curcumin (Curcuma, turmeric) and cancer. National Institutes of Health, U.S. Department of Health and Human Services. (Source: Curcumin (Curcuma, Turmeric) and Cancer.pdf)

10. Restivo, J. (2024). Turmeric benefits: A look at the evidence (T. Fung, Ed.). Harvard Health Publishing, Harvard Medical School. (Source: Turmeric benefits_ A look at the evidence - Harvard Health.pdf)

11. Różański, G., Tabisz, H., Zalewska, M., Niemiro, W., Kujawski, S., Newton, J., Zalewski, P., & Słomko, J. (2023). Meta-analysis exploring the effect of curcumin supplementation, with or without other advice, on biochemical and anthropometric parameters in patients with metabolic-associated fatty liver disease (MAFLD). International Journal of Environmental Research and Public Health, 20(5), Article 4266. (Source: ijerph-20-04266-v3.pdf)

12. Shen, W., Qu, Y., Jiang, H., Wang, H., Pan, Y., Zhang, Y., Wu, X., Han, Y., & Zhang, Y. (2022). Therapeutic effect and safety of curcumin in women with PCOS: A systematic review and meta-analysis. Frontiers in Endocrinology, 13, Article 1051111. (Source: fendo-13-1051111.pdf)

13. Zeng, L., Yang, T., Yang, K., Yu, G., Li, J., Xiang, W., & Chen, H. (2022). Curcumin and Curcuma longa extract in the treatment of 10 types of autoimmune diseases: A systematic review and meta-analysis of 31 randomized controlled trials. Frontiers in Immunology, 13, Article 896476. (Source: fimmu-13-896476.pdf)

14. Zeng, L., Yu, G., Hao, W., Yang, K., & Chen, H. (2021). The efficacy and safety of Curcuma longa extract and curcumin supplements on osteoarthritis: A systematic review and meta-analysis. Bioscience Reports, 41(6), Article BSR20210817. https://doi.org/10.1042/BSR20210817 (Source: bsr-2021-0817.pdf)

15. Zhao, J., Liang, G., Zhou, G., Hong, K., Yang, W., Liu, J., & Zeng, L. (2024). Efficacy and safety of curcumin therapy for knee osteoarthritis: A Bayesian network meta-analysis. Journal of Ethnopharmacology, 321, Article 117493. (Source: 1-s2.0-S0378874123013636-main.pdf)

Scientific evidence on curcumin’s role in cancer spans robust preclinical laboratory research, early-phase clinical trials for prevention and treatment, and supportive care for side effects of cancer therapy.

1. Preclinical Evidence and Biological Mechanisms

In cell lines and animal models, curcuminoids demonstrate broad multi-targeted activity across several pathways crucial to cancer development and progression:

• Cell Cycle & Proliferation: Downregulates cyclins (cyclin D1, cyclin E) and growth factor signaling pathways (HER-2, EGFR, AP-1).

• Apoptosis & Survival: Activates caspases, inhibits antiapoptotic genes, and suppresses PI3K/AKT survival pathways.

• Angiogenesis & Metastasis: Inhibits vascular endothelial growth factor (VEGF), CXC-chemokine receptor-4 (CXCR-4), and matrix metalloproteinase-9 (MMP-9).

• Inflammation: Suppresses master inflammatory regulators, including nuclear factor-kappa B (NF-κB), cyclooxygenase-2 (COX-2), 5-LOX, TNF-α, and interleukins (IL-1, IL-6, IL-8).

2. Cancer Prevention and Precancerous Lesions

Early-phase clinical trials in humans have explored curcumin for managing high-risk precancerous conditions:

• Oral Leukoplakia: A randomized phase IIB trial involving 223 patients showed that 3,600 mg/day of a curcuminoid-enriched preparation for 6 months achieved statistically significant clinical response rates (75 out of 105 patients) compared to placebo (62 out of 108 patients).

• Colorectal Precancerous Lesions: High-dose oral curcumin (4,000 mg/day for 30 days) significantly reduced the number of aberrant crypt foci (ACF) by 40%. However, studies on polyps in Familial Adenomatous Polyposis (FAP) yielded mixed results, with pure curcumin showing no significant difference compared to placebo.

• Plasma Cell Disorders (MGUS & SMM): In patients with monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM), 4,000-8,000 mg daily reduced the free light-chain ratio (rFLC) and markers of bone resorption.

3. Cancer Treatment (Monotherapy and Chemotherapy Adjunct)

Clinical evidence evaluating curcumin as a primary treatment or combined with standard chemotherapy remains in early pilot stages:

• Monotherapy: Small phase II pilot trials in advanced pancreatic cancer patients showed no treatment-related toxicity, but yielded only rare or transient responses (e.g., stable disease in isolated patients).

• FOLFOX (Colorectal Cancer): Combining oral curcumin (up to 2,000 mg/day) with FOLFOX chemotherapy (CUFOX) was safe and tolerable and showed a potential survival benefit in small Phase IIa trials, though larger trials are needed.

• Gemcitabine (Pancreatic Cancer): Unformulated curcumin at 8,000 mg/day caused significant gastrointestinal toxicity leading to high withdrawal rates. However, bioavailable phytosome formulations combined with gemcitabine were well-tolerated and showed an overall disease control rate of 61.4%.

• Docetaxel (Prostate Cancer): A randomized phase II trial combining docetaxel with 6 g/day of curcumin in metastatic castration-resistant prostate cancer showed no significant difference in progression-free survival, overall survival, or PSA response rate compared to docetaxel plus placebo.

4. Supportive Care and Side Effect Management

The strongest human clinical evidence for curcumin lies in ameliorating cancer treatment-related side effects:

• Radiation Dermatitis: Topical turmeric creams and oral curcumin reduced skin irritation and radiation dermatitis severity in breast cancer patients undergoing radiotherapy.

• Oral Mucositis: Curcumin and turmeric mouthwashes, as well as oral nano-curcumin formulations, significantly delayed the onset and reduced the severity of chemotherapy- and radiation-induced oral mucositis in head and neck cancer patients.

• Quality of Life & Inflammation: Bioavailable curcumin formulations improved self-reported quality-of-life scores and systemic oxidative status in patients undergoing chemotherapy and radiation.

5. Current Expert Consensus and Clinical Cautions

• Inadequate Clinical Evidence for Primary Therapy: Major regulatory bodies and integrative oncology programs (such as the National Cancer Institute PDQ and Memorial Sloan Kettering Cancer Center) emphasize that current evidence is inadequate to recommend curcumin for treating cancer or as a standard therapeutic adjunct. The FDA has not approved curcumin for cancer treatment.

• Drug Interactions: Patients undergoing active chemotherapy should consult their oncologists before taking curcumin supplements. Curcumin may interfere with the effectiveness of certain chemotherapeutic drugs, such as doxorubicin, cyclophosphamide, camptothecin, and mechlorethamine. High supplement doses can also cause liver toxicity, gastrointestinal upset, or increased bleeding risks.

References

1. Al-Maweri, S. A., Al-Qadhi, G., Alqutaibi, A. Y., Sallam, N. M., Assad, M., Abdulghani, M. A., & Mohammed, M. M. A. (2025). Curcumin versus corticosteroids for symptomatic oral lichen planus: A systematic review and meta-analysis. Clinical and Experimental Dental Research, 11(5), Article e70227. (Source: Clinical Exp Dental Res - 2025 - Al‐Maweri - Curcumin Versus Corticosteroids for Symptomatic Oral Lichen Planus A.pdf)

2. Cleveland Clinic Health Essentials. (2022). 6 health benefits of turmeric. (Source: Turmeric Health Benefits and Side Effects.pdf)

3. Hewlings, S. J., & Kalman, D. S. (2017). Curcumin: A review of its effects on human health. Foods, 6(10), Article 92. (Sources: foods-06-00092.pdf & foods-06-00092-v3.pdf)

4. Johns Hopkins Medicine. (2026). Turmeric benefits. Johns Hopkins Health Library. (Source: Turmeric Benefits _ Johns Hopkins Medicine.pdf)

5. Kou, H., Huang, L., Jin, M., He, Q., Zhang, R., & Ma, J. (2023). Effect of curcumin on rheumatoid arthritis: A systematic review and meta-analysis. Frontiers in Immunology, 14, Article 1121655. (Source: fimmu-14-1121655.pdf)

6. Liu, X., Lin, L., & Hu, G. (2024). Meta-analysis of the effect of curcumin supplementation on skeletal muscle damage status. PLoS ONE, 19(7), Article e0299135. (Source: journal.pone.0299135.pdf)

7. Memorial Sloan Kettering Cancer Center. (2026). The truth about turmeric and cancer. (Source: The Truth About Turmeric and Cancer _ Memorial Sloan Kettering Cancer Center.pdf)

8. Mokgalaboni, K., Mashaba, R. G., Phoswa, W. N., & Lebelo, S. L. (2024). Curcumin attenuates hyperglycemia and inflammation in type 2 diabetes mellitus: Quantitative analysis of randomized controlled trial. Nutrients, 16(23), Article 4177. (Source: nutrients-16-04177-v4.pdf)

9. National Cancer Institute. (2023). PDQ® curcumin (Curcuma, turmeric) and cancer. National Institutes of Health, U.S. Department of Health and Human Services. (Source: Curcumin (Curcuma, Turmeric) and Cancer.pdf)

10. Restivo, J. (2024). Turmeric benefits: A look at the evidence (T. Fung, Ed.). Harvard Health Publishing, Harvard Medical School. (Source: Turmeric benefits_ A look at the evidence - Harvard Health.pdf)

11. Różański, G., Tabisz, H., Zalewska, M., Niemiro, W., Kujawski, S., Newton, J., Zalewski, P., & Słomko, J. (2023). Meta-analysis of exploring the effect of curcumin supplementation with or without other advice on biochemical and anthropometric parameters in patients with metabolic-associated fatty liver disease (MAFLD). International Journal of Environmental Research and Public Health, 20(5), Article 4266. (Source: ijerph-20-04266-v3.pdf)

12. Shen, W., Qu, Y., Jiang, H., Wang, H., Pan, Y., Zhang, Y., Wu, X., Han, Y., & Zhang, Y. (2022). Therapeutic effect and safety of curcumin in women with PCOS: A systematic review and meta-analysis. Frontiers in Endocrinology, 13, Article 1051111. (Source: fendo-13-1051111.pdf)

13. Zeng, L., Yang, T., Yang, K., Yu, G., Li, J., Xiang, W., & Chen, H. (2022). Curcumin and Curcuma longa extract in the treatment of 10 types of autoimmune diseases: A systematic review and meta-analysis of 31 randomized controlled trials. Frontiers in Immunology, 13, Article 896476. (Source: fimmu-13-896476.pdf)

14. Zeng, L., Yu, G., Hao, W., Yang, K., & Chen, H. (2021). The efficacy and safety of Curcuma longa extract and curcumin supplements on osteoarthritis: A systematic review and meta-analysis. Bioscience Reports, 41(6), Article BSR20210817. https://doi.org/10.1042/BSR20210817 (Source: bsr-2021-0817.pdf)

15. Zhao, J., Liang, G., Zhou, G., Hong, K., Yang, W., Liu, J., & Zeng, L. (2024). Efficacy and safety of curcumin therapy for knee osteoarthritis: A Bayesian network meta-analysis. Journal of Ethnopharmacology, 321, Article 117493. (Source: 1-s2.0-S0378874123013636-main.pdf)

Years ago, a friend told me about turmeric's potential benefits. Soon after, I learned that adding black pepper could increase its absorption and effectiveness. Out came my pepper shaker!

After doing more research, I switched to taking a daily curcumin supplement instead of turmeric with black pepper. Curcumin is the active compound in turmeric, and supplements are readily available in capsule form. A couple of years later, I learned about a supposedly more effective option: liposomal curcumin, which I now take daily.

Research suggests curcumin may help fight several types of cancer. Joe Tippens was taking it when his cancer went into remission, and he currently recommends it as part of his Tippens Protocol, which also includes fenbendazole.

As with many products associated with alternative cancer treatments, online information spans a wide spectrum of claims. On one end, we find promising medical research, including preclinical laboratory and animal studies, human studies examining whether curcumin can help ease the side effects of cancer treatment, and limited clinical trials investigating curcumin alongside chemotherapy.

On the other end, we find unverified anecdotal claims about its effects on cancer and viral stories asserting that turmeric can outperform antidepressants, steroids, statins, blood thinners, chemotherapy drugs, and diabetes medications—all at once. The list of supposed miracle applications goes even further, with claims that curcumin can cure autism, Alzheimer’s disease, and multiple sclerosis.

Let’s take a closer look.

First, it’s important to understand that curcumin, a compound derived from turmeric, can interact with certain medications. These interactions may affect how medications work or increase side-effect risk. If you take prescription medications, don’t assume turmeric or curcumin supplements are safe to use without first checking with your doctor or pharmacist. Some combinations may require caution or should be avoided altogether.

Turmeric Supplements and Drug Interactions

High doses of curcumin in concentrated turmeric supplements can interact with certain medications.

• Pain relievers: Turmeric supplements can lessen the effects of indomethacin, aspirin, ibuprofen, or acetaminophen.

• Chemotherapy: If you are receiving chemotherapy treatments, talk to your doctor before taking turmeric supplements, and especially avoid them if you are taking these chemotherapy agents:

  • Camptothecin

  • Mechlorethamine

  • Doxorubicin

  • Cyclophosphamide

• Blood thinners: Turmeric or curcumin supplements can increase the risk of bleeding in people taking warfarin.

• Immunosuppressive drugs: People taking a medication called tacrolimus may experience increased side effects if they consume high amounts of curcumin.

Curcumin Clinical Efficacy

The following two articles examine the therapeutic efficacy and safety of curcumin, a natural compound derived from the Curcuma longa plant, in treating various inflammatory conditions and managing cancer symptoms. Research shows that curcumin has potent anti-inflammatory, antioxidant, and immunomodulatory properties, making it a promising alternative or adjunct to conventional treatments such as corticosteroids. Clinical trials on oral lichen planus indicate that curcumin effectively alleviates pain and improves lesions while causing fewer adverse effects than traditional therapies. Similarly, studies on cancer patients show that curcumin can help ameliorate treatment-related side effects, such as mucositis and radiation dermatitis, while improving overall oxidative status. However, the literature emphasizes that many existing trials have methodological limitations and a high risk of bias, underscoring the need for rigorous, well-powered studies with standardized formulations before curcumin can be recommended for widespread clinical use. No, pharmaceutical companies can’t patent it!

Article 2

Article 3

Oct 18, 2026

Niclosamide is a decades-old anti-parasitic drug now being studied for cancer, but the evidence is still mostly from cell and animal studies. It disrupts several pathways tumors rely on (STAT3, Wnt, mTOR, mitochondrial energy). Its main obstacle is poor absorption into the bloodstream, so many papers test new formulations and modified molecules.

Three cancer trials are currently active on ClinicalTrials.gov; all are small, early-phase studies.

NCT05188170

NCT02807805

NCT07683013

Sources

• PubMed search: niclosamide AND cancer

• ClinicalTrials.gov search: niclosamide in cancer conditions

This research investigates a novel combination therapy to overcome the limitations of single-agent approaches in cancer treatment, which often fail due to toxicity or the activation of compensatory metabolism. Using metabolically distinct breast cancer cell lines, the study shows that repurposing FDA-approved mitochondrial-targeting agents—such as niclosamide, IMD-0354, and pyrvinium pamoate—disrupts mitochondrial respiration but triggers an unwanted surge in glycolysis. To counteract this adaptation, researchers combined these mitochondrial poisons with BAY-876, a selective GLUT1 inhibitor, successfully shutting down glucose uptake and the compensatory pathway. Ultimately, this dual-targeting strategy induces a fatal metabolic crisis in cancer cells, highlighting the therapeutic potential of tailoring treatment regimens to a tumor’s specific nutrient handling and bioenergetic profile.

In combination therapies, newly engineered niclosamide prodrugs (such as NIC-PS and SSL-0024) and nanoengineered formulations (such as Penetrium) act as potent chemo- and immuno-sensitizers. They overcome drug resistance by simultaneously suppressing parallel survival networks, reducing immune-checkpoint expression, and dismantling structural microenvironmental barriers that block drug access.

1. Combination with Sorafenib (Targeted Kinase Therapy)

• Enhanced Sensitivity & Tumor Inhibition: Co-treatment of NIC-PS with sorafenib significantly increases the drug sensitivity of hepatocellular carcinoma (HCC) cells compared to sorafenib alone.

• Overcoming Resistance via VASN/TGF-β Axis: Multi-kinase inhibitors like sorafenib often fail due to adaptive activation of compensatory survival pathways (e.g., PI3K/AKT or RAF/MEK/ERK). Prodrugs such as NIC-PS and SSL-0024 directly bind and downregulate Vasorin (VASN), blocking downstream TGF-β/SMAD2/3 signaling.

• Multi-Pathway Network Suppression: In addition to VASN inhibition, SSL-0024 concurrently inhibits AKT, mTOR, STAT3, C-Raf, and Wnt/β-catenin signaling. This multi-target suppression prevents tumors from shifting to parallel pathways to escape sorafenib. In patient-derived organoids (PDOs), SSL-0024 alone achieved significantly greater cytotoxicity than sorafenib monotherapy, establishing a rationale for combined or follow-on treatment.

2. Combination with Immune Checkpoint Inhibitors (Anti-PD-1 / Anti-PD-L1)

• Direct PD-L1 Downregulation: Both NIC-PS and SSL-0024 significantly suppress PD-L1 mRNA and protein expression in cancer cells, largely by shutting down STAT3, a key transcriptional driver of PD-L1.

• Reversing TGF-β-Mediated Immune Escape: Elevated TGF-β in tumors acts as an immunosuppressive shield that restricts T-cell activity and impairs PD-L1 blockade. By inhibiting VASN and suppressing TGF-β signaling, NIC-PS re-sensitizes resistant HCC cells to anti-PD-L1 antibody treatment.

• Overcoming Physical Immune Exclusion (Penetrium Nanohybrid): In aggressive, desmoplastic models like triple-negative breast cancer (TNBC), anti-PD-1 monotherapy fails because a dense extracellular matrix (ECM) creates an “immune-excluded” phenotype. The niclosamide nanohybrid Penetrium remodels the ECM and depletes cancer-associated fibroblasts (CAFs). This allows CD8+ T cells to infiltrate the tumor parenchyma, restoring anti-PD-1 responsiveness and achieving near-complete suppression of lung metastasis.

3. Combination with Chemotherapy & Anti-Angiogenic Agents

• Paclitaxel (Chemotherapy): Combining Penetrium with paclitaxel in breast cancer models markedly reduces lung metastasis and reverses Epithelial-to-Mesenchymal Transition (EMT) by restoring E-cadherin and downregulating invasion markers like MMP-9 and S100A4.

• Gemcitabine (Pancreatic Organoid/CAF Co-Culture): In pancreatic cancer organoid co-cultures, cancer-associated fibroblasts normally drive severe chemoresistance to gemcitabine. Pre-treatment with niclosamide or Penetrium selectively eliminates CAFs, dismantling the protective stromal shield and restoring gemcitabine chemosensitivity.

• Bevacizumab (Anti-VEGF): Combining Penetrium with the anti-angiogenic agent bevacizumab synergistically downregulates both MMP-9 (matrix degradation) and VEGF (vascular formation), achieving up to 100% suppression of distant metastasis in lung carcinoma models.

• GLUT1 Inhibitors (Metabolic Blockade): Combining niclosamide (a mitochondrial uncoupler) with the GLUT1 inhibitor BAY-876 blocks the compensatory spike in glycolysis that cancer cells use to survive mitochondrial disruption, triggering a fatal metabolic crisis.

Schumacher, T. J., Iyer, A. V., Rumbley, J., Ronayne, C. T., & Mereddy, V. R. (2024). Repurposing mitochondrial-targeting anthelmintic agents with GLUT1 inhibitor BAY-876 for cancer therapy [Preprint]. bioRxiv.

Tan, M., Ye, W., Liu, Y., Chen, X., Huttad, L., Chua, M.-S., & So, S. (2024). Niclosamide prodrug enhances oral bioavailability and targets vasorin-TGFβ signaling in hepatocellular carcinoma [Preprint]. bioRxiv.

Rejinold, N. S., Kim, S. J., Jin, G.-W., & Choy, J.-H. (2025). Penetrium nanodrug remodels the tumor ECM to overcome pseudo-resistance and enhance anticancer therapeutic synergy [Preprint]. bioRxiv.

Tan, M., Schow, S., Liu, Y., Lum, R., Massoudi, D., Dhanasekaran, R., So, S., & Chua, M.-S. (2026). A novel niclosamide sulfate prodrug with enhanced bioavailability suppresses hepatocellular carcinoma via inhibition of multiple signaling pathways [Preprint]. bioRxiv.

Comparing the Diffuse Large B-Cell Lymphoma (DLBCL) case report with the three solid tumor cases (breast, prostate, and melanoma) reveals key differences in dosing strategies, treatment regimens, response timelines, and side-effect profiles across hematologic vs. solid malignancies.

Key Clinical Takeaways

1. Monotherapy vs. Multimodal Combinations:

   • The DLBCL case provides a rare example of FBZ as monotherapy, showing disease regression without concurrent chemo- or immunotherapy.

   • In contrast, all three solid tumor cases combined FBZ with non-chemotherapeutic standard options (such as hormonal blockade or immune checkpoint inhibitors), making it difficult to isolate FBZ’s exact individual contribution.

2. Dosing Tolerability & Toxicity Thresholds:

   • High Dosing (1,000 mg/day) in the DLBCL patient led to peripheral neuropathy, compelling the patient to scale down intake.

   • Low-to-moderate dosing (222–444 mg/day) in the solid tumor cases achieved near-complete or complete metabolic remissions without neurotoxicity or significant organ toxicity.

3. Response Speed:

   • The melanoma case exhibited the fastest response, with circulating tumor DNA dropping to zero in under 10 weeks. The hematologic DLBCL case showed a more gradual, step-wise regression over 6 to 11 months of continuous tapering.

Primary Case Report Publications

• Abughanimeh, O., Evans, T., & Kallam, A. (2020). Fenbendazole as a treatment for diffuse large B-cell lymphoma. Annals of Hematology & Oncology, 7(2), Article 1284.

• Makis, W., Baghli, I., & Martinez, P. (2025). Fenbendazole as an anticancer agent? A case series of self-administration in three patients. Case Reports in Oncology, 18(1), 864–875. https://doi.org/10.1159/000546362

Referenced Background & Preclinical Case Studies

• Chiang, R. S., Syed, A. B., Wright, J. L., Montgomery, B., & Srinivas, S. (2021). Fenbendazole enhancing anti-tumor effect: A case series. Clinical Oncology Case Reports, 4(2), Article 1.

• Gao, P., Dang, C. V., & Watson, J. (2008). Unexpected antitumorigenic effect of fenbendazole when combined with supplementary vitamins. Journal of the American Association for Laboratory Animal Science, 47(6), 37–40.

Small Bowel Net Appointment Guide

312KB ∙ PDF file

Download

Download

The Basics

Small bowel NETs that have reached the lymph nodes and liver are usually treatable for many years, often a decade or more for low-grade tumors. This guide gathers the questions, options, trials, and research to bring to appointments. It is background reading, not medical advice; the care team knows the specifics. For informational purposes only.

1. Where it starts: usually the ileum, the last part of the small intestine.

2. How it spreads: first to lymph nodes in the mesentery (the tissue that carries blood vessels to the bowel), then to the liver.

3. Why the mesentery matters: nodal spread can trigger scarring (fibrosis) that kinks the bowel or squeezes its blood supply. This is a common reason for surgery even when the liver is involved.

4. Key numbers to know: grade (G1, G2 or G3), Ki-67 percentage, whether tumors light up on a somatostatin receptor (SSTR) PET scan, and roughly what share of the liver is involved.

5. Carcinoid syndrome: flushing and diarrhea from hormones the tumor releases, most often once the liver is involved. It also puts the heart valves at risk, so regular echocardiograms matter.

Contents:

-Questions to ask the care team

-Treatment options at a glance

-Clinical trials currently recruiting

• Newly diagnosed, before other treatment

• After progression on somatostatin analogs (no prior PRRT)

• After prior PRRT

• Somatostatin analog questions

-Key research papers

-Appointment notes

Newly engineered prodrugs improve niclosamide (NIC) bioavailability for cancer therapy by directly addressing its main clinical limitations: extremely poor water solubility (~1.6 mg/L), a high melting point, and rapid systemic clearance, which otherwise prevent effective concentrations from reaching solid tumors.

These prodrugs overcome these barriers through several chemical and pharmacokinetic enhancements:

1. Significantly Increasing Water Solubility & Stability

• Phenolic Functional Modification: Modifying niclosamide's 2-hydroxyl phenol group with strongly anionic or polar groups drastically increases aqueous solubility.

• Gastric & Plasma Stability: For example, the O-sulfate ammonium salt prodrug SSL-0024 achieves a 2.2-fold increase in kinetic solubility and a 5-fold increase in thermodynamic solubility compared to native niclosamide6. It remains highly stable under gastric (pH 2.0) and physiological (pH 7.4) conditions, with 85.6% intact in human plasma, preventing premature degradation in circulation.

2. Dramatically Extending Systemic Exposure (AUC & Half-Life)

• Substantial Bioavailability Gains: The water-soluble prodrug NIC-PS achieves an almost 10-fold increase in oral bioavailability (Area Under the Curve, AUC) compared to native oral niclosamide.

• Sustained Release Profile: Unlike native niclosamide or earlier phosphate salt prodrugs that cause rapid plasma spikes followed by quick elimination11, compounds like SSL-0024 provide sustained release of active free niclosamide over 48 hours, resulting in 6.6-fold greater overall plasma exposure.

3. Targeted In Vivo Bioactivation & Safe Cleavage

• Enzymatic Conversion: Prodrugs act as soluble precursors that undergo cleavage in vivo to release active free niclosamide.

• Non-Toxic Byproducts: Endogenous aryl sulfatases in liver cells cleave SSL-0024 to release bioactive niclosamide alongside an ammonium sulfate counterion labeled as Generally Recognized As Safe (GRAS) by the FDA15. This avoids off-target toxicities (such as lung alveolar irritation) seen with older salt forms like niclosamide ethanolamine (NEN)1516.

4. Promoting Preferential Accumulation in Solid Tumors

• Higher Tumor-to-Tissue Ratio: Prolonged systemic circulation enables niclosamide to accumulate preferentially within tumor tissues rather than healthy surrounding tissue.

• In orthotopic hepatocellular carcinoma (HCC) patient-derived xenograft (PDX) models, NIC-PS achieves ~1.5-fold higher niclosamide concentrations in PDX tumors than in normal adjacent liver tissue17. Similarly, SSL-0024 achieves preferential tumor accumulation (~1.2-fold higher than normal liver at 48 hours) and achieves ~60% tumor growth inhibition at less than half (~45.8%) the molar equivalent dose of NEN18.

5. Complementary Nanohybrid Approaches

• Beyond pure chemical prodrugs, nanoengineered formulations such as Penetrium (a niclosamide–magnesium oxide–HPMC nanodrug) use ionic interactions and localized pH buffering to increase oral bioavailability, protect the compound, and enable penetration through dense, fibrotic extracellular matrix (ECM) barriers.

References

1. (2026). Niclosamide and cancer: Research and clinical trials [Research overview report].

2. Rejinold, N. S., Kim, S., Jin, G.-W., & Choy, J.-H. (2025). Penetrium nanodrug remodels the tumor ECM to overcome pseudo-resistance and enhance anticancer therapeutic synergy [Preprint]. bioRxiv.

3. Schumacher, T. J., Iyer, A. V., Rumbley, J., Ronayne, C. T., & Mereddy, V. R. (2024). Repurposing mitochondrial-targeting anthelmintic agents with GLUT1 inhibitor BAY-876 for cancer therapy [Preprint]. bioRxiv.

4. Tan, M., Ye, W., Liu, Y., Chen, X., Huttad, L., Chua, M.-S., & So, S. (2024). Niclosamide prodrug enhances oral bioavailability and targets vasorin-TGFβ signaling in hepatocellular carcinoma [Preprint]. bioRxiv.

5. Tan, M., Schow, S., Liu, Y., Lum, R., Massoudi, D., Dhanasekaran, R., So, S., & Chua, M.-S. (2026). A novel niclosamide sulfate prodrug with enhanced bioavailability suppresses hepatocellular carcinoma via inhibition of multiple signaling pathways [Preprint]. bioRxiv.

Although potential anticancer activities of benzimidazole-based anthelmintic drugs have been approved by preclinical and clinical studies, modes of binding interactions have not been reported so far. This study aimed to propose binding interactions between some benzimidazole-based anthelmintics and one of the most important cancer targets (Tubulin protein). Studied drugs were selected based on their structural similarity to the cocrystallized ligand (Nocodazole) with the tubulin protein. We also used quantum mechanics calculations to characterize the electronic configuration of the studied drugs at the atomic and molecular level. Order of binding affinities of tested benzimidazole drugs toward colchicine binding site on tubulin protein is as follows: Flubendazole > Oxfendazole > Nocodazole > Mebendazole > Albendazole > Oxibendazole > Fenbendazole > Ciclobendazole > Thiabendazole > Bendazole. By analyzing the binding mode and hydrogen-bond lengths between the nine studied benzimidazole drugs and the colchicine binding site, we found that Flubendazole binds more efficiently to the tubulin protein than the other benzimidazole derivatives. The quantum mechanics studies showed that the electron density of HOMO of Flubendazole and Mebendazole together with their MEP map are quite similar to that of Nocodazole which is also consistent with the calculated binding affinities. Our study supports considering the repurposing of Flubendazole as a promising anticancer candidate.

A molecular docking study examining benzimidazole-based anthelmintic drugs against tubulin protein (PDB ID: 5CA1) provides theoretical characterization of how Fenbendazole and its analogs interact with the colchicine binding site (CBS).

1. Target Active Site & Key Interactions

• Protein Target: The docking simulations used the crystal structure of tubulin complexed with the reference ligand Nocodazole (NZO) across two active-site pockets: Subunit B and the larger Subunit D.

• Crucial Amino Acids: Binding interactions in the colchicine-binding pocket primarily involve Glu198 and Val236 across both subunits, along with Asn165 in Subunit B, Cys239 in Subunit D, and hydrophobic interactions with Leu253.

2. Fenbendazole Binding Profile

• Docking Scores: Using the Molecular Operating Environment (MOE) software package, Fenbendazole achieved placement scores (S) of -7.09 in Subunit B and -7.39 in Subunit D.

• Hydrogen Bonding:

  • In Subunit B, Fenbendazole forms hydrogen bonds with Val236 (2.96 Å) and Glu198 (2.86 Å).

  • In Subunit D, it forms hydrogen bonds with Val236 (2.95 Å), Glu198 (3.03 Å), and Asn165 (2.81 Å).

• Hydrophobic Contact: It maintains stabilizing hydrophobic contacts with Leu253 in both subunits.

3. Relative Binding Affinity Ranking

When evaluated alongside eight other benzimidazole derivatives and the lead compound Nocodazole, the calculated binding affinity order toward the tubulin colchicine binding site is: Flubendazole>Oxfendazole>NZO (docked)>Mebendazole>Albendazole>Oxibendazole>Fenbendazole>Ciclobendazole>Thiabendazole>Bendazole

While Fenbendazole binds with high stability, flubendazole showed the strongest binding affinity, the highest docking score, and the closest fingerprint match to native Nocodazole.

4. Quantum Mechanics & DFT Calculations

• Density Functional Theory (DFT) calculations at the B3LYP/6-311+G* level revealed that the Highest Occupied Molecular Orbital (HOMO) electrons of Fenbendazole are localized mainly over its benzene moiety and aromatic side chain, exhibiting a different orbital distribution pattern than Nocodazole.

• Molecular Electrostatic Potential (MEP) mapping confirmed that the benzimidazole ring nitrogens function as electron-donating and electron-accepting sites capable of key hydrogen bonding within the tubulin binding pocket.

Flubendazole Tubulin Binding

Molecular docking and Quantum Mechanics/Density Functional Theory (DFT) calculations reveal that Flubendazole binds more effectively to the tubulin colchicine binding site (PDB ID: 5CA1) than other benzimidazole derivatives (including Fenbendazole) due to several structural and electronic features:

1. Fingerprint Binding Mode & Crucial Hydrogen Bonding

• Subunit B Interactions: Flubendazole exhibits a “fingerprint” binding mode nearly identical to the co-crystallized reference drug Nocodazole (NZO). It uniquely forms a hydrogen bond through the oxygen atom of its carbamate moiety with Asn165 (3.03 Å), closely matching native NZO (3.19 Å).

• Subunit D Water-Bridged H-Bonding: In Subunit D, Flubendazole re-establishes a crucial hydrogen bond with Cys239 via a bridging water molecule (H2O616, calculated at 3.14 Å). This mirrors the native NZO interaction—a feature lost in the docked NZO model.

• Conserved Active Site Contacts: Like top-performing inhibitors, Flubendazole maintains stable hydrogen bonds with Val236 and Glu198, along with hydrophobic contacts with Leu253.

2. Superior Docking Scores & Binding Affinity Ranking

• Top Placement Scores: In Molecular Operating Environment (MOE) simulations, Flubendazole achieved placement scores of S=−7.36 in Subunit B and S=−7.25 in Subunit D, outperforming docked NZO (−7.34 and −7.04) as well as Fenbendazole (−7.09 and −7.39).

• Calculated Affinity Order: Based on docking scores and physical parameters, Flubendazole ranks highest among all tested compounds: Flubendazole>Oxfendazole>NZO (docked)>Mebendazole>Albendazole>Oxibendazole>Fenbendazole>Ciclobendazole>Thiabendazole>Bendazole

3. Electronic Configuration & DFT Parameters

• HOMO Orbital Localization: DFT calculations (B3LYP/6-311+G* level) show that Flubendazole’s Highest Occupied Molecular Orbital (HOMO) electron density is localized primarily on the central benzimidazole core, closely matching the electronic distribution pattern of Nocodazole. In contrast, compounds like Fenbendazole have HOMO density delocalized over the benzene ring and side chains.

• Electrostatic Potential (MEP) Alignment: Flubendazole’s Molecular Electrostatic Potential map aligns closely with Nocodazole. Its 5(6)-substituted fluorobenzoyl group preserves the optimal electropositive/electronegative distribution required for hydrogen donation and acceptance within the binding pocket.

In computational drug research, docking scores (such as the placement score S in MOE) estimate a drug's theoretical binding affinity and structural fit within a target protein’s active site—in this case, the colchicine binding site (CBS) on tubulin.

While a more negative docking score indicates stronger, more stable binding to the isolated protein pocket, it does not translate directly into cellular cytotoxicity or clinical anticancer potency. The relationship between docking scores and real-world potency involves several factors:

1. Predictor of Binding Efficiency

Docking scores let researchers rank compounds by how well they fit the active site relative to a known reference drug. For example, the study ranked binding affinities toward the tubulin CBS as: Flubendazole>Oxfendazole>NZO (docked)>Mebendazole>Albendazole>Oxibendazole>Fenbendazole>Ciclobendazole>Thiabendazole>Bendazole. This ranking prioritizes compounds like Flubendazole as top candidates for targeting tubulin depolymerization.

2. Physical & Electronic Determinants Beyond Energy Scores

The study emphasizes that binding affinity and therapeutic interaction depend on more than calculated energy scores or orbital energies. They are governed by a complex set of physical determinants:

• Specific Hydrogen-Bonding Networks: Crucial interactions with key amino acids like Val236, Glu198, Asn165, and Cys239.

• Electrostatic & Van der Waals Forces: Molecular Electrostatic Potential (MEP) maps and hydrophobic contact with residues like Leu253.

• Water-Bridged Interactions: Solvent molecules (such as bridging water H2O616) stabilize binding inside the pocket.

3. Isolated Target vs. Whole-Cell Complexity

A docking score measures interaction with a single, rigid or semi-rigid protein structure in silico. In contrast, actual anticancer potency (IC50 or tumor suppression) in cell lines or animal models depends on broader biological processes:

• Cellular Uptake & Bioavailability: How effectively the drug crosses cell membranes to reach intracellular tubulin.

• Intracellular Accumulation & Efflux: Resistance mechanisms, such as P-glycoprotein efflux pumps, which affect how much drug stays inside the cell.

• Off-Target & Multi-Metabolic Effects: Anthelmintic drugs often engage additional cellular pathways (such as glucose metabolism disruption or ROS induction) that contribute to cell death beyond tubulin inhibition alone.

Summary

Docking scores are an essential first-line computational screening tool for identifying and prioritizing lead compounds that fit the tubulin binding site. However, researchers must validate full anticancer potency through in vitro cell assays and in vivo studies that account for cellular uptake, metabolic pathways, and systemic pharmacokinetics.

Source

Khattab, M., & Al-Karmalawy, A. A. (2021). Revisiting activity of some nocodazole analogues as a potential anticancer drugs using molecular docking and DFT calculations. Frontiers in Chemistry, 9, Article 628398

https://www.frontiersin.org/journals/chemistry/articles/10.3389/fchem.2021.628398/full

I’m making some changes to our Substack format, including a dedicated section for paid subscribers. Here’s what you can expect beginning November 1, 2026.

Free Subscribers

Free subscribers will continue to have full access to all articles published from the launch of our Substack through November 1, 2026—approximately 200 articles.

After November 1, free subscribers can expect 2–3 new articles per week, covering research, developments, and topics related to our ongoing focus on getting healthy.

Paid Subscribers

Beginning November 1, paid subscribers will have full access to all previously published articles, along with exclusive access to the new paid section. Paid subscribers can expect 5–15 new articles per week.

Additionally, paid subscribers can request that we research specific topics that matter to them. Whether you’re interested in a particular type of cancer, a drug, a supplement, a protocol, or a concern affecting you or a family member, let us know what you’d like us to investigate.

For example, if you want to learn more about breast cancer and fenbendazole, simply send us your request. We’ll review the latest published medical papers and other relevant evidence, then publish our findings within a few days.

Our goal is to provide more research, cover more topics, and help you find the information you’re looking for. Your questions and suggestions will help shape the content we produce, so please don’t hesitate to reach out with ideas for future articles.

Thank you for being part of our community and for joining us on this journey toward better health.

Carl

fenbendazolecancer@gmail.com

1. Fundamental Bio-Metabolic Mechanisms of Fenbendazole Disruption

Context & Strategic Importance

Repurposing non-oncology pharmaceuticals is a pivotal strategy in contemporary drug discovery, offering a faster path to clinical translation while reducing the exorbitant development costs and safety uncertainties of novel chemical entities. Fenbendazole [methyl N-(6-phenylsulfanyl-1H-benzimidazol-2-yl) carbamate; FBZ], an inexpensive, broad-spectrum benzimidazole anthelmintic routinely employed in veterinary medicine, has attracted rigorous scientific interest for its multifaceted antineoplastic properties. Malignant transformation involves structural plasticity and metabolic rewiring, features that often make mono-targeted therapeutics vulnerable to rapidly acquired resistance. By simultaneously destabilizing the tubulin cytoskeleton, activating p53-dependent stress cascades, inhibiting 26S proteasomal degradation, and enforcing upper glycolytic blockade, FBZ establishes a comprehensive multi-target therapeutic strategy capable of circumventing single-pathway resistance mechanisms.

Tubulin Dynamics and Cytoskeletal Perturbation

Microtubules are dynamic polymers of \alpha- and \beta-tubulin heterodimers essential for mitotic spindle assembly, intracellular vesicular transport, structural integrity, and cell motility. FBZ acts as a moderate microtubule-destabilizing agent, binding directly to mammalian tubulin at the colchicine-binding domain, as confirmed by competitive fluorescence binding assays. However, its biophysical impact on tubulin polymer kinetics differs markedly from classic, high-toxicity antimitotic agents like colchicine and nocodazole.

• Polymerization Kinetics: In cell-free assays using purified bovine tubulin, FBZ gently and concentration-dependently suppresses tubulin polymerization, contrasting sharply with the immediate, complete shutdown of assembly induced by colchicine.

• Soluble-to-Polymerized Tubulin Ratios: Quantitative subcellular fractionation and immunoblot analyses in A549 non-small cell lung carcinoma (NSCLC) models demonstrate that treatment with 1.0\,\mu\text{M} FBZ yields a modest increase in the soluble-to-polymerized tubulin ratio (\sim 1.5-fold elevation over baseline control). In comparison, nocodazole exposure yields a \sim 2.0-fold increase, while colchicine treatment produces a dramatic \sim 3.7-fold increase, rendering polymerized tubulin virtually unquantifiable.

• Tubulin Acetylation Status: Post-translational modifications, particularly \alpha-tubulin acetylation at Lysine-40 (\text{Ac-}\alpha\text{-tubulin}), serve as crucial determinants of microtubule structural stability and intracellular stress signal transduction. Aggressive destabilizers such as colchicine, nocodazole, and vincristine rapidly and robustly deacylate and deplete \text{Ac-}\alpha\text{-tubulin}. Conversely, FBZ treatment preserves stable baseline levels of acetylated \alpha-tubulin. Maintaining the acetylated tubulin pool preserves the structural conduits required for stress-mediated signal transduction, thereby facilitating intracellular transport and subsequent nuclear translocation of transcriptionally active tumor suppressors.

p53 Pathway Activation and Subcellular Translocation

A key mechanism driving FBZ-induced cytotoxicity is its ability to disrupt cellular protein degradation by inhibiting proteasomal activity. Under basal conditions, the tumor suppressor p53 is maintained at low physiological levels through continuous polyubiquitination by the E3 ubiquitin ligase MDM2, which targets it for rapid degradation by the 26S proteasome. FBZ-mediated proteasomal impairment disrupts this degradative pathway. Instead of full polyubiquitination and proteolysis, p53 accumulates primarily as a monoubiquitinated protein in the cytosol.

Monoubiquitination serves as a post-translational sorting signal that diverts p53 away from immediate degradation and directs it toward distinct subcellular compartments:

1. Nuclear Translocation and Transcriptional Activation: A portion of the accumulated p53 translocates to the nucleus in a dose-dependent manner. There, it acts as a transcriptionally active factor, binding specific response elements to upregulate pro-apoptotic genes and metabolic regulators.

2. Mitochondrial Translocation and MOMP Induction: Concurrently, monoubiquitinated p53 translocates to the outer mitochondrial membrane (OMM). At the OMM, p53 directly interacts with anti-apoptotic Bcl-2 family proteins (such as Bcl-2 and Bcl-xL), neutralizing their inhibitory effect on Bax/Bak oligomerization. This interaction triggers mitochondrial outer membrane permeabilization (MOMP), rapidly collapsing the mitochondrial electrochemical gradient (\Delta\Psi_m), as measured by JC-1 dye conversion. MOMP causes the rapid extravasation of cytochrome c into the cytosol, initiating assembly of the apoptosome, cleavage of poly(ADP-ribose) polymerase (PARP), and activation of downstream executioner caspases.

Direct Glycolytic Suppression and Enzyme Modulation

Cancer cells preferentially utilize high-rate glycolysis for ATP generation and metabolic intermediates even under normoxic conditions—the classic Warburg effect. FBZ directly disrupts this bioenergetic adaptation through a combination of catalytic enzyme inhibition and transcriptional reprogramming:

• Downregulation of GLUT-4 Transporters and Hexokinase II: FBZ treatment leads to marked transcriptional repression of glucose transporter 4 (GLUT-4) and hexokinase II (HKII). Functional tracking with the fluorescent, non-metabolizable analog 2-NBDG reveals a profound reduction in cellular glucose uptake, accompanied by decreased glucose oxidation and reduced extracellular lactate secretion.

• HKII Active-Site Mimicry: Beyond lowering transcript abundance, FBZ directly inhibits HKII enzymatic activity. Molecular modeling and in-silico docking studies demonstrate that FBZ structurally mimics both glucose and its phosphorylated product, glucose-6-phosphate (G6P). By binding tightly to HKII's active catalytic pocket, FBZ prevents substrate phosphorylation, causing a substrate-level phosphorylation arrest that halts upper glycolysis.

• Induction of Mitochondrial Succinate Dehydrogenase (SDH): While shutting down upper glycolytic flux, FBZ paradoxically enhances mitochondrial succinate dehydrogenase (Complex II of the electron transport chain) activity. SDH catalyzes the oxidation of succinate to fumarate within the tricarboxylic acid (TCA) cycle. Because intracellular succinate accumulation functions as an “oncometabolite” that stabilizes hypoxia-inducible factor 1-alpha (HIF-1\alpha), FBZ-mediated SDH activation reduces oncogenic succinate pools, exerting a tumor-suppressive metabolic effect.

• p53-Directed Metabolic Reprogramming: The nuclear pool of p53 activated by FBZ drives the expression of metabolic target genes that actively suppress Warburg-type glycolysis and re-establish oxidative flux. Key induced targets include GLS2 (Glutaminase 2) and PRODH/POX (Proline Oxidase), which shift amino acid metabolism toward mitochondrial entry, alongside TIGAR (TP53-Induced Glycolysis and Apoptosis Regulator) and SCO2 (Synthesis of Cytochrome c Oxidase 2). TIGAR reduces intracellular fructose-2,6-bisphosphate levels to slow glycolytic flux, while SCO2 optimizes assembly of the cytochrome c oxidase complex, redirecting bioenergetic dependencies toward mitochondrial oxidative phosphorylation.

Section Transition

By combining mild tubulin depolymerization, proteasomal blockade, monoubiquitinated p53 mitochondrial targeting, and direct catalytic HKII inhibition, FBZ functions as a pleiotropic, multi-target metabolic disruptor. However, the phenotypic expression and ultimate cytotoxic potency of these multi-target disruptions depend heavily on the baseline bioenergetic wiring and genomic background of individual tumor models.

2. Cross-Cell Line Comparative Sensitivity and Metabolic Profiling

Context & Strategic Importance

Malignant tissues exhibit significant metabolic and genomic heterogeneity. Determining whether a given tumor relies primarily on Warburg-type aerobic glycolysis or Pasteur-type oxidative phosphorylation, combined with its baseline p53 status, is critical for predicting therapeutic vulnerability to FBZ. Comparative profiling across defined cell lines establishes the biochemical determinants governing FBZ responsiveness and helps identify selective therapeutic windows.

Comprehensive Cell Line Response Matrix

The table below synthesizes empirical parameters, sensitivity profiles, genomic status, and redox modulation characteristics across tested cell line models evaluated under

Warburg vs. Pasteur Phenotypes and Selective Redox Modulation

Differential sensitivity to FBZ among breast model systems demonstrates a clear relationship between baseline bioenergetic wiring and intracellular redox fate:

• Warburg-Type Vulnerability (MDA-MB-231): Aggressive, triple-negative MDA-MB-231 cells rely predominantly on glycolytic flux regardless of oxygen tension. Treatment with 10\,\mu\text{M} FBZ for 48 hours induces strong intracellular oxidative stress. Dihydroethidium (DHE) assays demonstrate a \sim 2-fold increase in cytosolic superoxide (\text{O}_2^{\bullet-}), while DCFH-DA assays show a \sim 3-fold elevation in hydroperoxides. This sudden surge in reactive oxygen species (ROS) overwhelms the cell’s antioxidant capacity, exceeding the redox homeostatic threshold required to trigger apoptosis (IC_{50} = 10.50 \pm 0.81\,\mu\text{M}).

• Pasteur-Type Resilience (MCF-7): Luminal MCF-7 cells exhibit bioenergetic flexibility, maintaining mitochondrial oxidative phosphorylation under normoxia and shifting to glycolysis only under hypoxic challenge. Exposure to 10\,\mu\text{M} FBZ produces no detectable change in superoxide levels and yields only a mild \sim 1.5-fold increase in hydroperoxides. Consequently, these cells tolerate higher concentrations of the drug, displaying an IC_{50} of 75.00 \pm 5.25\,\mu\text{M}.

• Normal Cell Protective Mechanism (MCF-10A): In non-transformed MCF-10A epithelial cells, FBZ displays a paradoxical antioxidant and protective profile. Because these non-malignant cells maintain balanced mitochondrial respiration without hyper-activated upper glycolysis, FBZ treatment does not induce mitochondrial stress or outer membrane permeabilization. Instead, 10\,\mu\text{M} FBZ exposure decreases superoxide levels by \sim 2.5-fold and reduces hydroperoxides by \sim 2-fold relative to untreated controls by fine-tuning cellular reductive equivalents. While FBZ mildly suppresses MCF-10A proliferation, it does not induce direct cytotoxicity, producing an IC_{50} > 100.00\,\mu\text{M} (with maximum recorded cell death remaining below 20\%).

Role of p53 Status and Mitotic Arrest Dynamics

The apoptotic efficacy of FBZ is heavily governed by the functional status of the p53 gene product:

• p53 Genomic Dependency: Non-small cell lung carcinoma cells expressing functional wild-type p53 (A549, H460) experience rapid growth inhibition and apoptotic entry when exposed to 1.0\,\mu\text{M} FBZ. In contrast, p53-null (H1299) and p53-mutant (H522) lines show minimal growth suppression at the same concentration. Transfection and transient expression of wild-type p53 into p53-null H1299 cells fully restores sensitivity to FBZ-induced apoptosis, establishing wild-type p53 as an important mediator of FBZ toxicity.

• Mitotic Arrest Kinetics: Synchronized A549 cells exposed to FBZ display early elevation of Cyclin B1 and CDK1 protein complexes—detectable as early as 8 hours post-treatment, compared to 16 hours in untreated controls. This is accompanied by elevated levels of phosphorylated Histone H3 at Serine-10 [p-Histone H3 (Ser10)], a marker of active mitotic entry, at 12 and 24 hours.

• Caspase-Independent Mitotic Death: Prolonged arrest at the G_2/M transition forces cells into mitotic exit without completing cytokinesis. Unlike colchicine, which causes mitotic slip into an 8N polyploidy state, FBZ triggers direct mitotic cell death without polyploid intermediate formation. Furthermore, this apoptotic cascade is not blocked by the broad-spectrum pan-caspase inhibitor Z-VAD-FMK, confirming that FBZ can initiate caspase-independent mitotic cell death.

Efflux Pump Independence and MDR Compatibility

A key factor limiting traditional tubulin-binding drugs (such as taxanes and vinca alkaloids) is their susceptibility to multidrug resistance (MDR) mediated by ATP-binding cassette (ABC) efflux transporters, particularly P-glycoprotein (P-gp / MDR1).

• Rhodamine 123 Transport Assays: Intracellular accumulation assays using Rhodamine 123 (Rho123), a standard fluorescent substrate for P-gp efflux, show identical retention kinetics in untreated control cells and FBZ-treated cells.

• Verapamil Potentiation: Pharmacological blockade of P-gp using verapamil fails to increase intracellular Rho123 fluorescence or enhance FBZ-mediated cytotoxicity in A549 and H460 models.

• Therapeutic Implications: These experimental data demonstrate that FBZ is neither a substrate nor an inhibitor of P-gp. As a result, FBZ maintains cytotoxic potency in multidrug-resistant tumor models that readily efflux established chemotherapeutic drugs.

Section Transition

Because cellular sensitivity to FBZ is dictated by baseline metabolic wiring, functional p53 signaling, and P-gp independence, rational drug combinations can leverage these mechanisms to achieve dual bioenergetic collapse and overcome adaptive cell survival strategies.

3. Synergistic Metabolic Combinations: FBZ, Dichloroacetate (DCA), and 2-Deoxyglucose (2DG)

Context & Strategic Importance

Malignant cells frequently adapt to single-agent metabolic therapies by shifting flux through alternative bioenergetic pathways. To prevent compensatory survival adaptations, combining upper glycolytic inhibitors with mitochondrial pyruvate flux modulators and FBZ creates a multi-point metabolic blockade, driving tumor cells toward complete energetic failure.

Mechanistic Synergy with Dichloroacetate (DCA)

Dichloroacetate (DCA) is a selective inhibitor of pyruvate dehydrogenase kinase (PDK). By suppressing PDK, DCA maintains the pyruvate dehydrogenase (PDH) complex in an active, unphosphorylated state. This forces cytosolic pyruvate into the mitochondria, promoting pyruvate conversion to acetyl-CoA and increasing oxidative metabolism over lactic acid fermentation.

• Orthogonal Bioenergetic Collapse: Combining DCA with FBZ creates opposing metabolic forces within the cell. While DCA forces cells to rely on mitochondrial glucose oxidation, FBZ simultaneously downregulates GLUT-4, represses HKII expression, and directly blocks the catalytic activity of HKII. Forced flux into mitochondrial respiration during concurrent HKII blockade leads to rapid intracellular ATP depletion and severe metabolic stress.

• Quantitative Synergy Metrics: Formal iso-bologram and Combination Index (CI) analyses using the Chou-Talalay method reveal strong synergism for the FBZ + DCA combination, yielding a Combination Index of CI = 0.04 at the 50\% effective dose (ED_{50}). Because a CI < 1.0 reflects synergistic interaction (with CI < 0.1 indicating strong synergism), this combination demonstrates potent bioenergetic synergy.

Mechanistic Synergy with 2-Deoxyglucose (2DG)

2-Deoxyglucose (2DG) is a synthetic glucose analog that competitively inhibits upper glycolysis. Upon entering cells via GLUT transporters, 2DG is phosphorylated by hexokinase into 2-deoxyglucose-6-phosphate (2-DG-6-P). Unlike G6P, 2-DG-6-P cannot be processed by phosphoglucose isomerase, accumulating intracellularly and competitively inhibiting HKII.

• Dual-Point Upper Glycolytic Blockade: Co-administration of 2DG and FBZ creates a dual inhibition mechanism targeting hexokinase. While 2DG competes directly with endogenous glucose for phosphorylation, FBZ occupies the catalytic pocket of HKII and represses its transcriptional expression. This dual-action blockade halts early glycolytic processing, leading to reduced ATP production and suppressed lactate efflux.

• Quantitative Synergy Metrics: Quantitative interaction analysis confirms strong synergy between FBZ and 2DG at effective concentrations, yielding a Combination Index of CI = 0.21 at an affected fraction of Fa = 0.5.

Comparative Combination Metric Analysis

The table below summarizes quantitative synergy parameters, enzymatic targets, bioenergetic outcomes, and interaction classifications for FBZ paired with metabolic and microtubule-directed agents:

Section Transition

These robust preclinical combination metrics demonstrate clear in vitro synergistic efficacy. Examining how these multi-target metabolic mechanisms translate into whole-organism xenograft models and clinical self-administration protocols provides essential context for evaluating FBZ’s therapeutic potential.

4. Translational In Vivo Evidence and Clinical Case Synthesis

Context & Strategic Importance

Translating preclinical bioenergetic concepts into potential oncologic therapies requires evaluation in whole-organism tumor models and human case studies. Assessing oral bioavailability, systemic safety, tumor growth inhibition, and biomarker responses in these settings helps clarify the clinical viability of repurposed FBZ protocols.

Preclinical Xenograft Tumor Suppression

The in vivo therapeutic efficacy of oral FBZ was established using female athymic nu/nu mice bearing human A549 NSCLC xenografts (established tumor size 2\text{--}3\,\text{mm}).

• Experimental Dosing Protocol: Tumored animals received oral FBZ at 1.0\,\text{mg/mouse} every second day for 12 days.

• Tumor Volume and Weight Reduction: FBZ administration significantly reduced both gross tumor volume and total excised tumor mass compared with vehicle-treated controls.

• Anti-Angiogenic Activity: We evaluated intratumoral vascularization spectrophotometrically by measuring hemoglobin content (A_{590\text{nm}}) and histologically by CD31 endothelial staining. FBZ-treated xenografts showed a marked decrease in hemoglobin content and reduced CD31-positive vessel density, demonstrating clear in vivo anti-angiogenic activity.

• Intratumoral Apoptosis and p53 Induction: TUNEL staining revealed a high density of apoptotic cells in excised FBZ-treated tumor tissues. Immunohistochemical analyses confirmed increased intratumoral p53 expression, aligning with in vitro observations of p53-dependent apoptotic induction.

Clinical Real-World Translation (Case Series Analysis)

A clinical case series detailed advanced stage IV cancer patients who self-administered oral FBZ alongside their prescribed regimens (excluding conventional cytotoxic chemotherapy). The detailed clinical courses, biomarker dynamics, and follow-up metrics from these cases are summarized below:

Safety, Tolerability, and Methodological Limitations

Across both animal models and clinical self-administration reports, FBZ was generally well tolerated at oral doses ranging from 222\,\text{mg/day} to 444\,\text{mg/day}, without producing the systemic toxicities typical of conventional cytotoxic chemotherapy.

• Hepatic Safety Profile: In Case 1, routine blood testing revealed transient elevations in serum liver transaminases (ALT and AST) in July 2022. However, these enzyme levels normalized within weeks without medical intervention. It remains unclear whether this transient hepatic stress resulted from FBZ, fulvestrant, or an interaction between the two compounds. Case 2 reported no hepatic transaminase elevations or other drug-related side effects over 26 months of continuous therapy.

• Methodological Critique and Confounding Factors: While these clinical responses are encouraging, interpreting self-administered patient series requires careful analytical scrutiny:

  1. Confounding Therapeutic Modalities: All three patients received potent concurrent anti-neoplastic treatments. Case 1 received Fulvestrant (a selective estrogen receptor degrader) and targeted spinal radiotherapy; Case 2 received dual androgen deprivation therapy (Orgovix + Erleada) along with bone-modifying Xgeva; Case 3 underwent surgical tumor debulking and received two doses of Nivolumab (an anti-PD-1 immune checkpoint inhibitor). Because these concurrent treatments can induce disease responses on their own, we cannot attribute complete remissions solely to FBZ monotherapy.

  2. Observational Limitations: These data are limited by a small sample size (n=3), retrospective reporting, self-selection bias, and the absence of a control group.

  3. Need for Formal Clinical Evaluation: Patient-initiated self-medication occurs outside regulated trial settings, where drug purity, optimal dosing, and systematic toxicity monitoring cannot be guaranteed. Standardized Phase I/II clinical trials are necessary to define FBZ pharmacokinetics, long-term safety, and single-agent efficacy in human oncology.

Section Transition Summary

Preclinical studies and real-world case reports suggest that Fenbendazole represents an intriguing candidate for drug repurposing in oncology. Its multi-target mechanism—combining tubulin destabilization, p53 activation, proteasomal inhibition, and direct glycolytic disruption—provides a strong biological rationale for formal clinical evaluation. Well-designed, prospective clinical trials remain essential to definitively assess its safety, quantify its therapeutic efficacy, and establish standardized combination protocols for advanced malignancies.

Sources:

1. Armando, R. G., Mengual Gómez, D. L., & Gomez, D. E. (2020). Drug repositioning in oncology: Benzimidazole derivatives. International Journal of Oncology, 56(3), 651–684. [suspicious link removed]
   (Source files: Benzimidazole-derivatives.pdf & Benzimidazole-derivatives222.pdf)

2. Dogra, N., Kumar, A., & Mukhopadhyay, T. (2018). Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Scientific Reports, 8(1), Article 11926. https://doi.org/10.1038/s41598-018-30158-6
   (Source file: 41598_2018_Article_30158.pdf)

3. Ellison, A. (2026, July). Fenbendazole for lung cancer: Comprehensive research review 2026. Sanare Lab Science.
   (Source: Fenbendazole for Lung Cancer: Research Review 2026)

4. Hulscher, N., Victory, K., Thorp, J. A., Pinsky, D., Diaz-Villalobos, A., Gillooly, P., Coulson, F., Annazone, M., Radesi, C., Brooks, J., McCullough, P. A., & Risch, H. (2026). Real-world clinical outcomes of ivermectin and mebendazole in cancer patients: Results from a prospective observational cohort. Anticancer Research, 46(6), 3243–3255. [suspicious link removed]
   (Source file: 3243.full.pdf)

5. Ioakeim-Skoufa, I., Tobajas-Ramos, N., Menditto, E., Aza-Pascual-Salcedo, M., Gimeno-Miguel, A., Orlando, V., González-Rubio, F., Fanlo-Villacampa, A., Lasala-Aza, C., Ostasz, E., & Vicente-Romero, J. (2023). Drug repurposing in oncology: A systematic review of randomized controlled clinical trials. Cancers, 15(11), Article 2972. [suspicious link removed]
   (Source file: cancers-15-02972.pdf)

6. OneDayMD Editorial Team. (2026, September). Ivermectin, fenbendazole, mebendazole, niclosamide and atovaquone for cancer: Evidence, science, clinical trials & safety (F. Yap, Med. Rev.). One Day MD’s Newsletter.
   (Source: Fenbendazole and Ivermectin for Cancer: Real Stories, Science & Protocols (2025 Guide))

7. Tang, M., Hu, X., Wang, Y., Yao, X., Zhang, W., Yu, C., Cheng, F., Li, J., & Fang, Q. (2021). Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacological Research, 163, Article 105207. https://doi.org/10.1016/j.phrs.2020.105207
   (Source file: 1-s2.0-S1043661820315152-main.pdf)

8. Thorat, M. A. (2025). Aspirin prevents metastasis by limiting platelet TXA2 suppression of T cell immunity. BJC Reports. https://doi.org/10.1038/S41586-025-08626-7
   (Source file: 44276_2025_Article_138.pdf)

9. Wallis, B., Bowman, K. R., Lu, P., & Lim, C. S. (2023). The challenges and prospects of p53-based therapies in ovarian cancer. Biomolecules, 13(1), Article 159. [suspicious link removed]
   (Source file: biomolecules-13-00159.pdf)

This medical case report details an elderly patient diagnosed with stage IVa diffuse large B-cell lymphoma who declined conventional chemotherapy and instead self-administered fenbendazole, an animal deworming medication. Over a period of several months, follow-up imaging scans revealed a remarkable regression of the patient’s cancer and shrinking lymph nodes. While laboratory studies suggest this antiparasitic agent may disrupt cellular structures critical for tumor growth, the medical community notes that further clinical research is necessary to definitively establish its safety and efficacy as a human oncology treatment.

The published case report on Diffuse Large B-Cell Lymphoma (DLBCL) details an elderly patient who achieved significant disease regression after self-administering Fenbendazole as a monotherapy:

1. Patient Presentation & Diagnosis

• Clinical Profile: An 83-year-old male presented with heartburn, swallowing difficulties, and fatigue.

• Biopsy & Subtype: An esophagogastroduodenoscopy (EGD) revealed a superficial duodenal ulcer; biopsy confirmed DLBCL, Germinal Center B-cell (GCB) subtype.

• Genetics: Fluorescence in situ hybridization (FISH) was negative for c-MYC, BCL2, and BCL6 rearrangements.

• Staging: Baseline PET/CT showed hypermetabolic activity in the distal gastric antrum, proximal duodenum, peri-aortic lymph node, and pulmonary nodules, consistent with Stage IVa DLBCL.

2. Treatment Decisions & Fenbendazole Regimen

• Declining Standard Therapy: Given the aggressive nature of DLBCL, standard care called for urgent chemotherapy, which the patient declined due to concerns regarding side effects.

• Dosing Schedule: Based on self-directed research, the patient initiated oral Fenbendazole at 1 g daily (varying between 1 and 6 tablets daily according to his symptoms).

• Dose Modification: At 6 months, he reduced his dosage to 1–3 tablets daily after developing peripheral neuropathy.

3. Imaging Outcomes & Disease Timeline

• 6 Months: A chest CT ordered by his primary care physician revealed a reduction in the size of mediastinal lymph nodes.

• 8 Months: A follow-up PET/CT scan ordered by oncology showed marked improvement in overall lymphadenopathy compared to baseline.

• 11 Months: After further tapering Fenbendazole to 3 pills weekly, repeat PET/CT imaging showed continued interval regression of his lymphoma with no new lesions.

4. Scientific Context & Limitations

• Preclinical Precedent: The authors note that prior animal studies demonstrated antitumor activity for Fenbendazole, including a study by Gao et al. where Fenbendazole combined with supplementary vitamins significantly inhibited lymphoma growth in SCID mice.

• Authors’ Caution: The report emphasizes that while regression coincided with Fenbendazole intake, controlled clinical trials are needed to rule out confounding factors or spontaneous remission.

Comparing the Diffuse Large B-Cell Lymphoma (DLBCL) case report with the three solid tumor cases (breast, prostate, and melanoma) reveals key differences in dosing strategies, treatment regimens, response timelines, and side-effect profiles across hematologic vs. solid malignancies.

Key Clinical Takeaways

1. Monotherapy vs. Multimodal Combinations:

   • The DLBCL case provides a rare example of FBZ as monotherapy, showing disease regression without concurrent chemo- or immunotherapy.

   • In contrast, all three solid tumor cases combined FBZ with non-chemotherapeutic standard options (such as hormonal blockade or immune checkpoint inhibitors), making it difficult to isolate FBZ’s exact individual contribution.

2. Dosing Tolerability & Toxicity Thresholds:

   • High Dosing (1,000 mg/day) in the DLBCL patient led to peripheral neuropathy, compelling the patient to scale down intake.

   • Low-to-moderate dosing (222–444 mg/day) in the solid tumor cases achieved near-complete or complete metabolic remissions without neurotoxicity or significant organ toxicity.

3. Response Speed:

   • The melanoma case exhibited the fastest response, with circulating tumor DNA dropping to zero in under 10 weeks. The hematologic DLBCL case showed a more gradual, step-wise regression over 6 to 11 months of continuous tapering.

     ---

References

• Abughanimeh, O., Evans, T., & Kallam, A. (2020). Fenbendazole as a treatment for diffuse large B-cell lymphoma. Annals of Hematology & Oncology, 7(2), Article 1284.

• Dogra, N., Kumar, A., & Mukhopadhyay, T. (2018). Fenbendazole acts as a moderate microtubule-destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Scientific Reports, 8(1), Article 11926. https://doi.org/10.1038/s41598-018-30158-6

• Makis, W., Baghli, I., & Martinez, P. (2025). Fenbendazole as an anticancer agent? A case series of self-administration in three patients. Case Reports in Oncology, 18(1), 864–875. https://doi.org/10.1159/000546362

• Park, D., Lee, J.-H., & Yoon, S.-P. (2022). Anti-cancer effects of fenbendazole on 5-fluorouracil-resistant colorectal cancer cells. Korean Journal of Physiology & Pharmacology, 26(5), 377–387. https://doi.org/10.4196/kjpp.2022.26.5.377

• Semkova, S., Nikolova, B., Tsoneva, I., Antov, G., Ivanova, D., Angelov, A., Zhelev, Z., & Bakalova, R. (2023). Redox-mediated anticancer activity of anti-parasitic drug fenbendazole in triple-negative breast cancer cells. Anticancer Research, 43(3), 1207–1212.

Research indicates that the common anthelmintic medication fenbendazole functions as an effective anticancer agent by interfering with multiple cellular processes in malignant cells. Specifically, the drug acts as a moderate microtubule-destabilizing agent that disrupts the cellular skeleton and halts cell division, ultimately forcing cancer cells into apoptosis. Furthermore, the treatment suppresses tumor growth by blocking cellular glucose uptake and crippling key metabolic enzymes that aggressive cancer cells rely on to survive. These antitumor effects are further amplified by p53 activation and mitochondrial translocation, which work alongside the drug’s microtubule-disrupting activity. Ultimately, because the compound strongly suppresses tumors in both cell culture and live animal models without relying on traditional resistance pathways, it has significant potential for therapeutic repurposing in modern oncology.

Fenbendazole (FZ), a veterinary benzimidazole anthelmintic, demonstrates potent anticancer efficacy through a multi-targeted mechanism that combines moderate microtubule disruption, p53 pathway activation, metabolic suppression, and anti-angiogenesis.

1. Moderate Microtubule Destabilization

• Mechanism & Binding: Fenbendazole binds mammalian tubulin at the colchicine-binding site.

• Mild Depolymerization: Unlike colchicine or vincristine, which cause massive microtubule destruction, FZ mildly destabilizes the microtubule framework without altering acetylated α-tubulin levels.

• Mitotic Arrest: FZ induces a G2/M cell cycle block, elevating Cyclin B1, CDK1, and p-histone H3 (Ser10), leading cancer cells to undergo mitotic catastrophe and apoptosis.

2. Overcoming Multidrug Resistance (MDR)

• Non-P-gp Substrate: FZ is neither a substrate nor an inhibitor of P-glycoprotein (P-gp / MDR1).

• Bypassing Resistance: Co-treatment with the P-gp inhibitor verapamil does not alter FZ’s cytotoxicity, allowing FZ to bypass common multidrug resistance mechanisms that impair conventional chemotherapeutics like taxanes and vinca alkaloids.

3. p53 Activation & Mitochondrial Apoptosis

• p53 Dependency: Cancer cell lines expressing wild-type (WT) p53 (such as A549 and H460) display significantly higher sensitivity to FZ compared to p53-mutant or null cell lines.

• Nuclear Accumulation: FZ drives nuclear accumulation of WT p53 and induces downstream target genes including p21, MDM2, TIGAR, SCO2, and GLS2.

• Mitochondrial Translocation: FZ promotes direct translocation of monoubiquitinated p53 to mitochondria, depolarizing the mitochondrial membrane potential and triggering apoptosis.

4. Suppression of Glucose Metabolism (Warburg Effect Interruption)

• Glucose Uptake Blockade: FZ markedly reduces cellular glucose uptake and consumption while lowering lactate secretion in cancer cells.

• Hexokinase II (HKII) & GLUT-4 Inhibition: FZ down-regulates GLUT-4 transporters and directly inhibits Hexokinase II (HKII) by stably binding to its glucose/glucose-6-phosphate pocket.

• Succinate Dehydrogenase (SDH) Activation: FZ enhances SDH activity, a mitochondrial tumor suppressor enzyme, helping restore normal mitochondrial oxidative dynamics.

5. Synergistic Combination Therapies

FZ displays strong synergistic cytotoxicity (Combination Index (CI)<1) when combined with metabolic inhibitors and chemotherapeutics:

• Dichloroacetate (DCA) (CI≈0.04, indicating strong synergism).

• 2-deoxyglucose (2DG) (CI≈0.21).

• Taxol / Paclitaxel (CI≈0.52).

6. In Vivo Tumor Suppression & Anti-Angiogenesis

• Tumor Growth Reduction: In A549 mouse xenograft models, oral FZ (1 mg/mouse every 2 days) markedly reduced tumor volume and weight.

• Anti-Angiogenesis: FZ significantly reduced tumor vascularity, as shown by lower tumor hemoglobin content and a sharp decline in CD31-positive endothelial cells in tumor tissue.

In preclinical research, the ketogenic diet (KD) facilitates drug transport and accumulation in brain tissue, though the exact molecular mechanism remains incompletely understood.

Key findings regarding how KD impacts blood-brain barrier (BBB) delivery include:

• Lipid Solubilization & Bioavailability: Lipophilic small molecules like mebendazole have poor oral solubility on their own, but co-administration with a high-fat ketogenic diet improves gastrointestinal solubilization and systemic bioavailability.

• Enhanced Small-Molecule Transport Across the BBB: Nutritional ketosis facilitates the delivery of structurally diverse small-molecule therapeutics across the blood-brain barrier. For example, brain tumor delivery of the glutamine antagonist DON was three-fold greater in mice fed a ketogenic diet compared to those on a standard high-carbohydrate diet.

• Target Engagement & Brain Accumulation: MALDI imaging mass spectrometry confirmed mebendazole presence and accumulation directly in brain tumor tissues when delivered alongside KD. Similarly, co-administering KD with the mitochondrial inhibitor CPI-613 (devimistat) significantly reduced target enzymes like OGDH in brain tissue, whereas CPI-613 administered on a standard diet did not.

• Current Mechanistic Limitation: The authors explicitly note as a study limitation that the precise physiological or cellular mechanisms by which nutritional ketosis alters blood-brain barrier transport kinetics remain unclear and require further investigation.

Peer-Reviewed Journal Articles

• Dogra, N., Kumar, A., & Mukhopadhyay, T. (2018). Fenbendazole acts as a moderate microtubule-destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Scientific Reports, 8(1), Article 11926. https://doi.org/10.1038/s41598-018-30158-6

• Gupta, R., Roy, D., Ghosh, A., Begum, Y., Ghosh, D., & Swarnakar, S. (2025). Mebendazole exerts anticancer activity in ovarian cancer cell lines via novel Girdin-mediated AKT/IKKα/β/NF-κB signaling axis. Cells, 14(2), Article 113.

Preprint Publication

• Mukherjee, P., Maurer, J., Stopka, S. A., Greenwood, B., Aristizabal-Henao, J. J., Karmacharya, S., Chimento, A., Ta, N., Lee, D. C., Duraj, T., Bronson, R. T., Kiebish, M. A., & Seyfried, T. N. (2023). Ketogenic diet as a metabolic vehicle for enhancing the therapeutic efficacy of mebendazole and devimistat in preclinical high-grade gliomas grown in juvenile mice. bioRxiv.

Clinical Trial Registry Record

• Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. (2022). Phase I study of mebendazole therapy for recurrent/progressive pediatric brain tumors (Identifier: NCT02644291). National Library of Medicine (US). https://clinicaltrials.gov/study/NCT02644291

Module 1: Mebendazole in Pediatric Brain Tumors & Clinical Trial NCT02644291

1.1 Disease Burden and Pediatric High-Grade Glioma (HGG) Dynamics

Pediatric high-grade gliomas (HGGs) represent the primary cause of cancer-related mortality in children within the United States. Classified under WHO diagnostic criteria into anaplastic astrocytoma, diffuse intrinsic pontine glioma (DIPG), and pediatric glioblastoma (GBM), these tumors have seen virtually no improvement in management or overall survival outcomes in over a decade. Standard clinical management—surgical resection, radiotherapy, corticosteroids, and alkylating agents like temozolomide—offers modest therapeutic benefit but imposes severe, lifelong adverse effects and treatment burdens on long-term survivors.

A defining pathophysiological characteristic of pediatric HGGs is their higher rate of distant dissemination through cerebrospinal fluid (CSF) than adult malignant gliomas. While spinal cord dissemination occurs in 2% to 14% of adult glioma cases at recurrence, pediatric malignant gliomas exhibit a marked risk of distant relapse and leptomeningeal spread. Tumor tissue in DIPG and GBM is heavily infiltrated by cells expressing microglial/macrophage markers, constituting 30% to 50% of the total tumor cell population. These mesenchymal-origin neoplastic cells exhibit amoeboid motility, facilitating deep parenchymal infiltration and dissemination throughout the central nervous system (CNS) via Scherer’s structures and CSF pathways.

1.2 Preclinical Model Systems

To replicate the invasive and metabolic phenotypes of pediatric CNS tumors, specific syngeneic mouse models and human cell lines are utilized:

• VM-M3 Glioblastoma: A highly aggressive, invasive mesenchymal tumor that arose spontaneously in the cerebral cortex of an adult VM/Dk mouse. When orthotopically implanted into juvenile mice (postnatal days p21–p25, corresponding developmentally to human children aged 3–7 years), VM-M3 cells invade extensively from the cerebral cortex into the spinal column and meninges via the CSF. This model reproduces the distal leptomeningeal dissemination characteristic of pediatric HGG.

• CT-2A Glioblastoma: An anaplastic astrocytoma/neural stem cell tumor induced by 20-methylcholanthrene implantation in C57BL/6J mice. CT-2A tumors are highly angiogenic but strictly non-invasive.

• VM-NM1 Glioblastoma: A non-invasive glioblastoma stem cell tumor line derived from VM/Dk mice, expressing neural stem cell markers without distal spinal cord invasion.

• SF-188: An established human pediatric glioblastoma cell line utilized for in vitro metabolic and apoptotic evaluations.

[ Tumor Models & Invasive Patterns ]
├── VM-M3 (Mesenchymal, VM/Dk host) ──> Distal CSF invasion, Spinal cord/Meningeal spread
├── CT-2A (Neural Stem Cell, C57BL/6J) ──> Highly angiogenic, Strictly Non-Invasive
├── VM-NM1 (Stem Cell, VM/Dk host) ──> Non-Invasive intracranial growth
└── SF-188 (Human Pediatric GBM) ──> In vitro human pediatric translation model

1.3 Clinical Trial Parameters and Repurposing Context

Mebendazole (MBZ; methyl 5-benzoyl-1H-benzimidazol-2-ylcarbamate) is a repurposed synthetic benzimidazole anthelmintic with established preclinical efficacy against glioblastoma and medulloblastoma.

• Clinical Trial NCT01837862: A Phase I open-label clinical trial initiated to evaluate the safety, tolerability, and maximum tolerated dose (MTD) of mebendazole in pediatric patients with newly diagnosed, recurrent, or refractory high-grade gliomas.

• Clinical Trial NCT02644291: An interventional clinical trial designed to assess parameters surrounding therapeutic interventions and drug regimens in oncology.

1.4 Blood-Brain Barrier (BBB) Penetration and MALDI Mass Spectrometry Imaging

A critical hurdle in neuro-oncology is delivering drugs effectively across the blood-brain barrier. We definitively demonstrated mebendazole’s CNS penetration and tissue accumulation using Matrix-Assisted Laser Desorption/Ionization (MALDI) Mass Spectrometry Imaging (MSI).

• Instrumentation & Method: We analyzed brain tissue cryosections (10 \mum thickness) on a timsTOF fleX mass spectrometer in positive-ion Multiple Reaction Monitoring (MRM) mode.

• MRM Transition: The specific fragment transition monitored was m/z\ 296.103 \rightarrow 264.077 (isolation width 3 m/z, collision energy 15 eV), corresponding to the precursor ion [C_{16}H_{13}N_3O_3 + H]^+ yielding the product ion [C_{15}H_{10}N_3O_2 + H]^+ (exact mass 264.08).

• Matrix Application: 2,5-dihydroxybenzoic acid (80 mg/mL in 70:30 methanol: water with 0.1% TFA and 1% DMSO) applied via a TM Sprayer.

• Detection Results: High-intensity signals (yellow pixel distributions) confirmed robust MBZ accumulation throughout the tumor-bearing brain parenchyma of mice receiving MBZ with a ketogenic diet, whereas untreated control brains showed no background signal.

[ Precursor Ion: m/z 296.103 ] ──(CID / 15 eV)──> [ Product Ion: m/z 264.077 ]
                      (Exact Mass: 264.08)

1.5 Dosing Schedule, Proliferative Arrest, and Toxicity Profile

• Dosing Schedule: In preclinical juvenile mouse models (p21–p25), MBZ was administered orally, thoroughly mixed into a Ketogenic Diet (KD), at a dosage of 100 mg/kg body weight for 3 consecutive days per week (pulsed schedule).

• Proliferative Suppression: Immunostaining for Ki-67, a marker of cellular proliferation, showed a marked reduction in positive cells in treated brain tumors at both the primary tumor mass and the brain-tumor interface compared with standard-diet controls.

• Histopathology: Hematoxylin and Eosin (H&E) staining revealed widespread tumor cell death and destruction of the primary tumor mass without parenchymal invasion in KD + MBZ-treated mice.

• Systemic Safety Profile: Unlike conventional cytotoxic chemotherapy (e.g., temozolomide), MBZ demonstrated high systemic tolerability:

  • Liver Architecture: Histological examination of liver tissues from KD + MBZ groups showed normal hepatic lobular structure without enlarged hepatocytes, focal necrosis, or immune cell/inflammatory infiltration.

  • Enzymatic Safety: Serum Alanine Transaminase (ALT) activity levels remained completely normal and comparable between control and treated groups.

Module 1 Review Questions

1. Analytical Evaluation: Why is orthotopic brain implantation of VM-M3 cells in juvenile mice (p21–p25) superior to adult mouse models for studying pediatric high-grade glioma (HGG)?

2. Mass Spectrometry Protocol: Describe the specific MALDI MRM mass spectrometry parameters (precursor ion, product ion, collision energy, and matrix) used to confirm mebendazole penetration across the blood-brain barrier.

3. Pathophysiologic Mechanism: Contrast the invasive and structural growth patterns of the VM-M3 glioma model with the CT-2A and VM-NM1 models.

4. Toxicity Profile: What specific histological and biochemical markers demonstrated that pulsed mebendazole combined with a ketogenic diet avoids systemic hepatic toxicity?

Module 2: Ketogenic Metabolic Therapy & Press-Pulse Strategy

2.1 The Press-Pulse Therapeutic Framework

Cancer management using ketogenic metabolic therapy (KMT) operates on the Press-Pulse strategy framework:

• Metabolic Press: High-carbohydrate standard diets elevate blood glucose, driving tumor fermentation, inflammation, and edema (often exacerbated by standard radiotherapy and dexamethasone/steroid therapy). KMT acts as a continuous metabolic “press.” By restricting dietary carbohydrates and elevating fat intake, KMT reduces blood glucose, suppresses insulin/IGF-1 signaling, elevates non-fermentable neuroprotective ketone bodies (\beta-hydroxybutyrate), lowers systemic inflammation, suppresses tumor angiogenesis, and creates persistent bioenergetic stress in tumor cells.

• Pharmacological Pulse: Compromised cancer cells under metabolic stress become hypersensitive to targeted bioenergetic inhibitors. Short-term, periodic administration (”pulsing”) of small-molecule metabolic inhibitors—such as Mebendazole (MBZ), Devimistat (CPI-613), or 6-Diazo-5-oxo-L-norleucine (DON)—delivers lethal cytotoxic “pulses” to tumor cells while sparing normal, ketone-adapted neural tissues.

                  [ PRESS-PULSE THERAPEUTIC STRATEGY ]
                                   │
      ┌────────────────────────────┴────────────────────────────┐
      ▼                                                         ▼
[ METABOLIC PRESS: KMT ]                                [ PHARMACOLOGICAL PULSE ]
- Lowers Blood Glucose                                  - Mebendazole (MBZ): 100 mg/kg (3x/wk)
- Elevates Ketone Bodies (β-OHB)                        - Devimistat (CPI-613): 0.5–1.0 mg/kg (1x/wk)
- Reduces GKI to ≤ 2.0                                  - DON: 1.0 mg/kg (1–2x/wk)
- Inhibits Angiogenesis & Inflammation                  - Targeted Cytotoxic Destruction

2.2 Nutritional Ketosis as a Drug Delivery Vehicle

A crucial discovery in pediatric neuro-oncology is that nutritional ketosis acts as a delivery vehicle that enhances the brain delivery and therapeutic index of co-administered small molecules:

1. Bioavailability Enhancement: Highly lipophilic or low-solubility drugs like mebendazole show poor oral absorption on standard high-carbohydrate diets. Co-administration within a high-fat ketogenic matrix enhances systemic absorption and bioavailability.

2. Blood-Brain Barrier Facilitation: Nutritional ketosis alters blood-brain barrier permeability dynamics, increasing parenchymal concentrations of small molecules like DON, MBZ, and CPI-613.

3. Dose Reduction & Toxicity Mitigation: Enhanced CNS delivery allows lower pharmacological doses to achieve optimal tumor kill, preventing host toxicity.

2.3 Targeting Dual Fermentation Pathways: Glycolysis and Glutaminolysis

Malignant gliomas possess damaged mitochondrial oxidative phosphorylation (OxPhos). To meet energy demands and synthesize biomass, tumor cells depend simultaneously on two fermentation pathways:

1. Cytoplasmic Glucose Fermentation (Warburg Effect): Converts glucose to lactate despite the presence of oxygen.

2. Mitochondrial Glutamine Fermentation: Driven by glutaminolysis, in which glutaminase C (GAC) converts glutamine to glutamate—an enzyme gatekeeper that is highly overexpressed in aggressive brain tumors compared with normal tissue. Glutamate enters the TCA cycle to drive mitochondrial substrate-level phosphorylation (mSLP) at the succinyl-CoA ligase step, yielding ATP and succinate.

[ Cytoplasm ]    Glucose ──(Glycolysis)──> Pyruvate ──> Lactate + ATP (Warburg Effect)
                                                               │
[ Mitochondria ] Glutamine ──(Glutaminase C)──> Glutamate ──> α-KG ──(α-KGDH/OGDH)──> Succinyl-CoA ──(mSLP)──> Succinate + ATP

2.4 Pharmacological Mechanisms of Bioenergetic Inhibition

• Mebendazole (MBZ):

  • Glycolytic Suppression: Inhibits glucose uptake and glycolytic enzymes. LC-MS metabolomics reveals reduced intracellular levels of lactate, glycolytic intermediates, and precursors for nucleotide and fatty acid biosynthesis (malonyl-CoA).

  • Glutaminolysis Suppression: In vitro assays in VM-M3 cells demonstrate that MBZ selectively abolishes proliferation and viability when glutamine is the sole available nutrient substrate. LC-MS metabolite profiling shows marked reductions in glutamate, \alpha-ketoglutarate (\alpha-KG), and succinate, along with elevations in 2-aminobutyrate and aspartate.

  • Enzymatic Down-regulation: Western blot analysis demonstrates that MBZ significantly down-regulates Glutaminase C (GAC) protein expression in treated brain tumors in vivo.

  • Oxygen Consumption Rate (OCR): Real-time bioenergetic monitoring (Resipher system) demonstrates that MBZ (1 \muM) significantly suppresses OCR over 6 hours.

• Devimistat (CPI-613):

  • Mitochondrial Dehydrogenase Inhibition: A lipoate derivative that selectively targets lipoate-requiring mitochondrial enzyme complexes: Pyruvate Dehydrogenase (PDH) and 2-Oxoglutarate Dehydrogenase (OGDH / \alpha-ketoglutarate dehydrogenase).

  • Synergistic Dependency: CPI-613 alone on a Standard Diet (SD) fails to inhibit VM-M3 tumor growth in vivo. However, when paired with KMT, CPI-613 significantly decreases ex vivo brain bioluminescence, lowers OGDH protein levels (116 kDa band) in brain tumor tissue, and significantly prolongs overall mouse survival in both VM-M3 and CT-2A glioma models.

• 6-Diazo-5-oxo-L-norleucine (DON):

  • Unselective, robust glutamine antagonist used as a positive control. When pulsed (1.0 mg/kg i.p.) alongside KMT + MBZ, the tri-combination achieves over a 3-fold extension in overall survival in juvenile HGG mouse models.

2.5 Dietary Formulations and Systemic Physiological Parameters

The dietary compositions and blood physiological responses established in preclinical juvenile mouse studies (p21–p25) include:

[ Dietary Macronutrient Profiles ]
Standard Diet (SD):  [ Carbohydrates 62% ] [ Protein 27% ] [ Fat 7.2% ] (4.4 Kcal/g)
Ketogenic Diet (KD): [ Fat 72% ] [ Protein 15% ] [ Carbs 3% ] (7.1 Kcal/g)

• Blood Glucose: Significantly reduced from 8.0–11.0 mM in SD-fed mice down to 5.0–7.0 mM in KD-fed mice.

• Blood \ beta-hydroxybutyrate (\beta-OHB): Elevated from 0.7–2.0 mM in SD-fed controls to 3.3–3.9 mM in KD-fed mice.

• Glucose Ketone Index (GKI): Calculated as [\text{Glucose (mM)}] / [\text{Ketones (mM)}]. KMT consistently drives GKI values down to \le 2.0.

• Weight Maintenance: Ad libitum KetoGEN feeding maintained steady body weight in juvenile mice during critical development without causing growth retardation or lethargy.

Module 2 Review Questions

1. Conceptual Integration: Differentiate between the “press” and “pulse” components of Ketogenic Metabolic Therapy when treating pediatric high-grade gliomas.

2. Biochemical Calculations: Given a patient with a blood glucose reading of 5.4 mM and a blood \beta-hydroxybutyrate reading of 2.7 mM, calculate the Glucose Ketone Index (GKI). State whether this falls within the target therapeutic range for metabolic oncology.

3. Metabolic Pathway Analysis: How do mebendazole and devimistat (CPI-613) complement nutritional ketosis in targeting the dual fermentation pathways of glioblastoma cells?

4. Enzymatic Target Mechanisms: Detail the specific enzymatic targets inhibited by devimistat (CPI-613) and mebendazole within mitochondrial pathways.

Module 3: Fenbendazole Anticancer Mechanisms

3.1 Chemical Profile and Veterinary Repurposing Strategy

Fenbendazole (FZ; methyl N-(6-phenylsulfanyl-1H-benzimidazol-2-yl) carbamate) is a broad-spectrum benzimidazole anthelmintic widely approved for veterinary applications across multiple animal species. Repurposing veterinary anthelmintics for human oncology offers a cost-effective, high-efficiency pathway because of their established safety margins, low host toxicity, and high tolerability in animal toxicology studies.

            O
            ║
     S ─── [ Benzimidazole Core ] ─── NH ─── C ─── O ─── CH₃

3.2 Microtubule Dynamics and Structural Classification

Microtubules are dynamic polymers made of \alpha- and \beta-tubulin heterodimers that support cell division, mitotic spindle formation, intracellular trafficking, motility, and maintenance of cell morphology. Microtubule-targeting agents (MTAs) used in oncology fall into two functional classes:

1. Microtubule-Stabilizing Agents: Promote tubulin assembly and prevent depolymerization (e.g., paclitaxel, docetaxel, epothilones, discodermolide).

2. Microtubule-Destabilizing Agents: Inhibit tubulin polymerization and disrupt microtubule network assembly.

Fenbendazole is categorized as a microtubule-destabilizing agent. Like vinca alkaloids (vinblastine, vincristine, vinorelbine, vindesine, vinflunine), estramustine, colchicine, and combretastatins, fenbendazole binds tubulin to arrest microtubule polymerization dynamics.

[ Microtubule Targeting Agents ]
├── Stabilizing Agents (Prevent Depolymerization) ──> Paclitaxel, Docetaxel, Epothilones
└── Destabilizing Agents (Inhibit Polymerization) ──> Fenbendazole, Vinca Alkaloids, Colchicine

3.3 Mitotic Arrest and Pleiotropic Mechanisms

• Metaphase Arrest: By interfering with mitotic spindle assembly during M-phase, fenbendazole disrupts mechanical chromosome segregation, capturing dividing tumor cells in metaphase arrest.

• Apoptotic Induction: Prolonged M-phase arrest triggers intracellular apoptotic cascades, leading to programmed cell death in proliferating cancer cells.

• Pleiotropic Action vs. Single-Target Resistance: Tumorigenesis involves alterations across interconnected cell signaling networks. Single-target antineoplastic drugs frequently induce treatment resistance through bypass mutations. Fenbendazole exerts pleiotropic, multi-target activity by simultaneously perturbing structural, mitotic, and metabolic networks, reducing the likelihood of acquired drug resistance.

Module 3 Review Questions

1. Structural Classification: Compare the mechanisms of microtubule-stabilizing agents versus microtubule-destabilizing agents. Into which category does fenbendazole fall?

2. Cell Cycle Effects: What specific cell cycle stage is disrupted by fenbendazole, and what structural events precipitate this arrest?

3. Resistance Circumvention: Explain why the pleiotropic mechanism of benzimidazole anthelmintics provides an advantage over highly selective single-target chemotherapies.

Module 4: Mebendazole Potency, Bioenergetic Monitoring, and Apoptotic Signatures

4.1 Comparative In Vitro Potency and Proliferative Inhibition

Mebendazole (MBZ) displays potent cytotoxic and antiproliferative action across multiple preclinical glioblastoma models:

• VM-M3 (Mesenchymal Glioblastoma): MBZ suppresses cellular ATP content and bioluminescence in a strict dose-dependent manner. Brightfield microscopy demonstrates extensive cell death at 10 \muM MBZ. In vitro substrate-substitution experiments confirm that MBZ-induced viability reduction is significantly greater when cells depend on glutamine than on glucose.

• SF-188 (Human Pediatric Glioblastoma): In SF-188/luc cells, MBZ (1 \muM) and CPI-613 (100 \muM) significantly suppress bioluminescence and cell viability at both 24 and 48 hours post-treatment.

[ Bioluminescence / ATP Reduction in SF-188 ]
Untreated Control ──(24h / 48h)──> High Viability Signal
MBZ (1 µM)         ──(24h / 48h)──> Significant Reduction (p < 0.05)
CPI-613 (100 µM)   ──(24h / 48h)──> Significant Reduction (p < 0.05)

4.2 Apoptotic Pathways and Caspase Activation

In both murine VM-M3 glioblastoma cells and human pediatric SF-188 glioblastoma cells, mebendazole (1 \muM) and devimistat (100 \muM) induce programmed cell death via apoptotic signaling pathways:

• Caspase-3 Activation: Western blot analysis shows progressive, time-dependent cleavage and activation of caspase-3 after exposure to MBZ or CPI-613 at 24 and 48 hours.

• Metabolic Apoptosis Link: Apoptosis induction directly follows the depletion of cellular ATP reserves caused by simultaneous inhibition of glycolytic and glutaminolytic substrate-level phosphorylation.

[ Bioenergetic Stress ] ──> [ ATP Depletion ] ──> [ Caspase-3 Cleavage ] ──> [ Apoptotic Cell Death ]

4.3 Real-Time Resipher Oxygen Consumption Rate (OCR) Bioenergetics

To directly measure the bioenergetic impact of MBZ and devimistat (CPI-613) on live tumor cell respiration, real-time micro-coaxial oxygen sensing was performed using the Resipher optical sensing system:

• Experimental Protocol: VM-M3 cells seeded at 2.0 \times 10^5 cells/well in 96-well plates were incubated in serum-free DMEM containing 12 mM glucose and 2 mM glutamine.

• OCR Suppression: Continuous real-time monitoring over 6 hours showed that MBZ (1 \muM) or CPI-613 (100 \muM) treatment statistically significantly reduced real-time Oxygen Consumption Rate (OCR) compared with untreated vehicle controls.

• Bioenergetic Significance: This rapid OCR reduction confirms that MBZ and CPI-613 directly and acutely inhibit mitochondrial bioenergetics and respiratory chain function in glioblastoma cells.

                      [ REAL-TIME OCR MONITORING (Resipher System) ]
                                            │
           ┌────────────────────────────────┴────────────────────────────────┐
           ▼                                                                 ▼
[ MBZ Treatment (1 µM) ]                                        [ CPI-613 Treatment (100 µM) ]
- Significant OCR suppression at 6 hours                        - Significant OCR suppression at 6 hours
- Depletes mitochondrial respiration                            - Inhibits PDH/OGDH dehydrogenase complexes

Module 4 Review Questions

1. Bioenergetic Assays: What specific real-time changes in oxygen consumption rate (OCR) did the Resipher sensing system record after exposure to mebendazole and devimistat?

2. Molecular Apoptosis: Describe the Western blot evidence confirming that mebendazole triggers programmed cell death in human SF-188 glioblastoma cells.

3. Metabolic Metabolomics: Summarize the changes in metabolite concentrations (glutamate, succinate, lactate, malonyl-CoA, 2-aminobutyrate) observed via LC-MS in mebendazole-treated tumor cells.

4. In vivo survival outcomes: Compare survival outcomes in juvenile mice bearing VM-M3 tumors treated with a Ketogenic Diet alone versus a Ketogenic Diet combined with pulsed Mebendazole and DON.

Peer-Reviewed Journal Articles

1. Dogra, N., Kumar, A., & Mukhopadhyay, T. (2018). Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Scientific Reports, 8(1), Article 11926. https://doi.org/10.1038/s41598-018-30158-6
   (Source: 41598_2018_Article_30158.pdf)

2. Gupta, R., Roy, D., Ghosh, A., Begum, Y., Ghosh, D., & Swarnakar, S. (2025). Mebendazole exerts anticancer activity in ovarian cancer cell lines via novel Girdin-mediated AKT/IKKα/β/NF-κB signaling axis. Cells, 14(2), Article 113. (Source: cells-14-00113.pdf)

Preprint Publication

3. Mukherjee, P., Maurer, J., Stopka, S. A., Greenwood, B., Aristizabal-Henao, J. J., Karmacharya, S., Chimento, A., Ta, N., Lee, D. C., Duraj, T., Bronson, R. T., Kiebish, M. A., & Seyfried, T. N. (2023). Ketogenic diet as a metabolic vehicle for enhancing the therapeutic efficacy of mebendazole and devimistat in preclinical high-grade gliomas grown in juvenile mice. BioRxiv. (Source: 2023.06.09.544252v2.full.pdf)

Clinical Trial Registry Records

4. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. (2015–2022). Phase I study of mebendazole therapy for recurrent/progressive pediatric brain tumors (Identifier: NCT02644291). National Library of Medicine (US). https://clinicaltrials.gov/study/NCT02644291
   (Source: NCT02644291.pdf)

5. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. (2022). Phase I study of mebendazole therapy for recurrent/progressive pediatric brain tumors: Researcher view ([suspicious link removed] Identifier: NCT02644291). National Library of Medicine (US). https://clinicaltrials.gov/study/NCT02644291
   (Source: Researcher View _ NCT02644291 _ Phase I Study of Mebendazole Therapy for Recurrent_Progressive Pediatric Brain Tumors

The ketogenic diet has been studied in cancer mostly as an adjunct/supportive therapy, with the strongest human evidence showing it is generally feasible and can improve metabolic markers and quality of life.

Papers worth reading first

• Systematic review of cancer patients: 46 publications, 39 studies, 770 patients; concluded evidence is low quality, heterogeneous, and not conclusive for antitumor or overall survival benefit.

• Systematic review in adults with cancer: 11 studies, 102 participants; mixed effects on tumor outcomes and QoL, with low adherence common.

• Meta-analysis of randomized trials: KD lowered glucose but did not significantly improve cholesterol, IGF-1, weight, or QoL overall; evidence was insufficient for firm conclusions.

• Breast cancer RCT: KD reduced fasting glucose and body fat and showed higher overall survival in the neoadjuvant subgroup, with no severe adverse effects.

• Breast cancer RCT on chemo: KD lowered insulin, reduced tumor size in locally advanced disease, but did not improve response rate in metastatic disease.

• Glioblastoma phase 1 trial: KD with standard-of-care was safe and feasible, with high adherence and stable or improved QoL/cognition, but efficacy still needs randomized confirmation.

• Glioma systematic review: 23 studies, 306 patients; ketosis and safety were achievable, but OS/PFS benefits remained unproven and inconsistent.

• KETOCOMP rectal/breast radiotherapy studies: showed feasibility and improved QoL/metabolic health during radiotherapy or radio-chemotherapy, but not clear survival benefit.

• Review focused on mechanisms and translation: argues KD should be viewed as a stratified metabolic intervention rather than a universal anticancer therapy.

Bottom line

KD is a biologically plausible and usually feasible adjunct in oncology, but current human evidence supports it more strongly for metabolic/QoL benefits than for definitive anticancer efficacy or survival improvement. The field’s main limitation is that many studies are small, heterogeneous, and cancer-specific, so the most defensible use today is as a carefully supervised adjunct, not a proven stand-alone cancer treatment.

References

1. Römer, M., Dörfler, J., Hüebner, J. (2021) The use of ketogenic diets in cancer patients: a systematic review. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-021-00710-2

2. Ylikomi, T., Nées, M. (2026) Ketogenic Diet as an Adjuvant in Epithelial Cancers: Mechanisms, Model Systems, and Translational Opportunities. Cancers. https://doi.org/10.3390/cancers18162600

3. Zhao, H., Jin, H., Xian, J., (...), Bai, X. (2022) Effect of Ketogenic Diets on Body Composition and Metabolic Parameters of Cancer Patients: A Systematic Review and Meta-Analysis. Nutrients. https://doi.org/10.3390/nu14194192

4. Salido-Bueno, B., Gil-Hernández, E., Rueda-Ruzafa, L., (...), Cardona, D. (2024) Effects of ketogenic diets on cancer-related variables: A systematic review and meta-analysis of randomised controlled trials. Nutrition Bulletin. https://doi.org/10.1111/nbu.12693

5. Lyle, Nazmun, Hossain, Chowdhury Mobaswar, Pramanik, Krishna (2026) Therapeutic targeting of lipid metabolism in cancer: Mechanisms, pathways, and translational prospects. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2026.156507

6. Alhamzah, S.A., Gatar, O.M., Alruwaili, N.W. (2023) Effects of ketogenic diet on oxidative stress and cancer: A literature review. Advances in Cancer Biology - Metastasis. https://doi.org/10.1016/j.adcanc.2023.100093

7. Neha, Chaudhary, R. (2024) Ketogenic diet as a treatment and prevention strategy for cancer: A therapeutic alternative. Nutrition. https://doi.org/10.1016/j.nut.2024.112427

8. Allen, B.G., Bhatia, S.K., Anderson, C.M., (...), Fath, M.A. (2014) Ketogenic diets as an adjuvant cancer therapy: History and potential mechanism. Redox Biology. https://doi.org/10.1016/j.redox.2014.08.002

9. Khodabakhshi Fard, A., Akbari, M.E., Mirzaei, H.R., (...), Davoodi, S.H. (2020) Feasibility, Safety, and Beneficial Effects of MCT-Based Ketogenic Diet for Breast Cancer Treatment: A Randomized Controlled Trial Study. Nutrition and Cancer. https://doi.org/10.1080/01635581.2019.1650942

10. Klement, R.J., Weigel, M.M., Sweeney, R.A. (2021) A ketogenic diet consumed during radiotherapy improves several aspects of quality of life and metabolic health in women with breast cancer. Clinical Nutrition. https://doi.org/10.1016/j.clnu.2021.01.023

11. Klement, R.J., Meyer, D., Kanzler, S., Sweeney, R.A. (2022) Ketogenic diets consumed during radio-chemotherapy have beneficial effects on quality of life and metabolic health in patients with rectal cancer. European Journal of Nutrition. https://doi.org/10.1007/s00394-021-02615-y

12. Tan-Shalaby, J.L., Carrick, J., Edinger, K., (...), Shah, R.B. (2016) Modified Atkins diet in advanced malignancies - Final results of a safety and feasibility trial within the Veterans Affairs Pittsburgh Healthcare System. Nutrition and Metabolism. https://doi.org/10.1186/s12986-016-0113-y

13. Klement, R.J. (2017) Beneficial effects of ketogenic diets for cancer patients: a realist review with focus on evidence and confirmation. Medical Oncology. https://doi.org/10.1007/s12032-017-0991-5

14. Sremanakova, J., Sowerbutts, A.M., Burden, S. (2018) A systematic review of the use of ketogenic diets in adult patients with cancer. Journal of Human Nutrition and Dietetics. https://doi.org/10.1111/jhn.12587

15. Buga, A., Harper, D.G., Sapper, T.N., (...), Volek, J.S. (2024) Feasibility and metabolic outcomes of a well-formulated ketogenic diet as an adjuvant therapeutic intervention for women with stage IV metastatic breast cancer: The Keto-CARE trial. PLoS ONE. https://doi.org/10.1371/journal.pone.0296523

16. Augustus, E., Granderson, I., Rocke, K.D. (2021) The Impact of a Ketogenic Dietary Intervention on the Quality of Life of Stage II and III Cancer Patients: A Randomized Controlled Trial in the Caribbean. Nutrition and Cancer. https://doi.org/10.1080/01635581.2020.1803930

17. Klement, R.J., Sweeney, R.A. (2026) Survival outcomes of rectal and head and neck cancer patients receiving radio(chemo)therapy with a ketogenic diet. A post-hoc analysis from the KETOCOMP trial. Strahlentherapie und Onkologie. https://doi.org/10.1007/s00066-025-02499-5

18. Amaral, L.J., Gresham, G., Kim, S., (...), Hu, J. (2025) A phase 1 safety and feasibility trial of a ketogenic diet plus standard of care for patients with recently diagnosed glioblastoma. Scientific Reports. https://doi.org/10.1038/s41598-025-06675-6

19. Yang, Y.-F., Mattamel, P.B., Joseph, T., (...), Ming, W.-K. (2021) Efficacy of low-carbohydrate ketogenic diet as an adjuvant cancer therapy: A systematic review and meta-analysis of randomized controlled trials. Nutrients. https://doi.org/10.3390/nu13051388

20. AlMutairi, H., Mccullough, F., Siddiqui, K., (...), Dandapani, M. (2025) Safety, Feasibility, and Effectiveness of Ketogenic Diet in Pediatric Patients With Brain Tumors: A Systematic Review. Journal of Nutrition and Metabolism. https://doi.org/10.1155/jnme/7935879

21. Al-Taie, A., Elmasri, J. (2025) Prospects of the therapeutic approaches of ketogenic diet on the clinical outcomes of cancer: A scoping review. Bulletin du Cancer. https://doi.org/10.1016/j.bulcan.2025.05.012

22. Valerio, J., Borro, M., Proietti, E., (...), Alvarez-Pinzon, A.M. (2024) Systematic Review and Clinical Insights: The Role of the Ketogenic Diet in Managing Glioblastoma in Cancer Neuroscience. Journal of Personalized Medicine. https://doi.org/10.3390/jpm14090929

23. Li, R., Huang, Q., Ye, C., (...), Wang, Y. (2022) Bibliometric and visual analysis in the field of ketogenic diet on cancer from 2012 to 2021. Frontiers in Nutrition. https://doi.org/10.3389/fnut.2022.1060436

24. Khodabakhshi Fard, A., Akbari, M.E., Mirzaei, H.R., (...), Davoodi, S.H. (2021) Effects of Ketogenic metabolic therapy on patients with breast cancer: A randomized controlled clinical trial. Clinical Nutrition. https://doi.org/10.1016/j.clnu.2020.06.028

25. Persiani, M., Dallolio, L., Masini, A., (...), Sacchetti, R. (2026) Ketogenic Diet in the Treatment of Malignant Gliomas: A Systematic Review. Nutrients. https://doi.org/10.3390/nu18132166

26. Klement, R.J., Schäfer, G., Sweeney, R.A. (2020) A ketogenic diet exerts beneficial effects on body composition of cancer patients during radiotherapy: An interim analysis of the KETOCOMP study. Journal of Traditional and Complementary Medicine. https://doi.org/10.1016/j.jtcme.2019.03.007

In preclinical research, the ketogenic diet (KD) facilitates drug transport and accumulation in brain tissue.

Key findings regarding how KD impacts blood-brain barrier (BBB) delivery include:

• Lipid Solubilization & Bioavailability: Lipophilic small molecules like mebendazole have poor oral solubility on their own, but co-administration with a high-fat ketogenic diet improves gastrointestinal solubilization and systemic bioavailability.

• Enhanced Small-Molecule Transport Across the BBB: Nutritional ketosis facilitates the delivery of structurally diverse small-molecule therapeutics across the blood-brain barrier. For example, brain tumor delivery of the glutamine antagonist DON was three-fold greater in mice fed a ketogenic diet compared to those on a standard high-carbohydrate diet.

• Target Engagement & Brain Accumulation: MALDI imaging mass spectrometry confirmed mebendazole presence and accumulation directly in brain tumor tissues when delivered alongside KD. Similarly, co-administering KD with the mitochondrial inhibitor CPI-613 (devimistat) significantly reduced target enzymes like OGDH in brain tissue, whereas CPI-613 administered on a standard diet did not.

• Current Mechanistic Limitation: The authors explicitly note as a study limitation that the precise physiological or cellular mechanisms by which nutritional ketosis alters blood-brain barrier transport kinetics remain unclear and require further investigation.

Ketone bodies (such as \(\beta\)-hydroxybutyrate) selectively protect healthy brain and body tissues during metabolic therapy through a fundamental bioenergetic difference between normal and cancerous cells:

1. Sustaining Healthy Cells with Alternative Mitochondrial Fuel

Healthy neural and peripheral tissues possess fully functional mitochondria capable of normal oxidative phosphorylation (OxPhos). When carbohydrate restriction lowers systemic blood glucose and raises circulating ketone bodies, healthy cells readily adapt by oxidizing these non-fermentable ketones as an efficient, neuroprotective energy source to generate cellular ATP.

2. Exploiting Cancer’s Mitochondrial Defect (OxPhos Insufficiency)

In contrast, malignant brain tumor cells harbor well-documented structural and functional defects in their mitochondrial OxPhos machinery. Because cancer cells cannot efficiently metabolize ketone bodies for energy, they remain strictly dependent on cytoplasmic aerobic glucose fermentation (the Warburg effect) and glutamine fermentation to survive.

3. Preventing Systemic Energy Starvation and Organ Toxicity

By shifting the body’s primary circulating fuel from glucose to ketone bodies (lowering the Glucose-Ketone Index), ketogenic therapy starves fuel-dependent tumor cells while keeping normal brain cells fully nourished via ketone respiration. This bioenergetic protection allows targeted drug interventions (such as mebendazole or devimistat) to be administered at reduced or pulsed dosages, achieving potent anti-tumor activity without causing weight loss, tissue necrosis, or liver toxicity in healthy organs.

The ketogenic diet used for cancer treatment.

The ketogenic diet has been studied in cancer mostly as an adjunct/supportive therapy, with the strongest human evidence showing it is generally feasible and can improve metabolic markers and quality of life, while clear survival or tumor-control benefit remains unproven and inconsistent across cancers and study designs.

Papers worth reading first

• Systematic review of cancer patients: 46 publications, 39 studies, 770 patients; concluded evidence is low quality, heterogeneous, and not conclusive for antitumor or overall survival benefit.

• Systematic review in adults with cancer: 11 studies, 102 participants; mixed effects on tumor outcomes and QoL, with low adherence common.

• Meta-analysis of randomized trials: KD lowered glucose but did not significantly improve cholesterol, IGF-1, weight, or QoL overall; evidence was insufficient for firm conclusions.

• Breast cancer RCT: KD reduced fasting glucose and body fat and showed higher overall survival in the neoadjuvant subgroup, with no severe adverse effects.

• Breast cancer RCT on chemo: KD lowered insulin, reduced tumor size in locally advanced disease, but did not improve response rate in metastatic disease.

• Glioblastoma phase 1 trial: KD with standard-of-care was safe and feasible, with high adherence and stable or improved QoL/cognition, but efficacy still needs randomized confirmation.

• Glioma systematic review: 23 studies, 306 patients; ketosis and safety were achievable, but OS/PFS benefits remained unproven and inconsistent.

• KETOCOMP rectal/breast radiotherapy studies: showed feasibility and improved QoL/metabolic health during radiotherapy or radio-chemotherapy, but not clear survival benefit.

• Review focused on mechanisms and translation: argues KD should be viewed as a stratified metabolic intervention rather than a universal anticancer therapy.

Bottom line

KD is a biologically plausible and usually feasible adjunct in oncology, but current human evidence supports it more strongly for metabolic/QoL benefits than for definitive anticancer efficacy or survival improvement. The field’s main limitation is that many studies are small, heterogeneous, and cancer-specific, so the most defensible use today is as a carefully supervised adjunct, not a proven stand-alone cancer treatment.

References

1. Römer, M., Dörfler, J., Hüebner, J. (2021) The use of ketogenic diets in cancer patients: a systematic review. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-021-00710-2

2. Ylikomi, T., Nées, M. (2026) Ketogenic Diet as an Adjuvant in Epithelial Cancers: Mechanisms, Model Systems, and Translational Opportunities. Cancers. https://doi.org/10.3390/cancers18162600

3. Zhao, H., Jin, H., Xian, J., (...), Bai, X. (2022) Effect of Ketogenic Diets on Body Composition and Metabolic Parameters of Cancer Patients: A Systematic Review and Meta-Analysis. Nutrients. https://doi.org/10.3390/nu14194192

4. Salido-Bueno, B., Gil-Hernández, E., Rueda-Ruzafa, L., (...), Cardona, D. (2024) Effects of ketogenic diets on cancer-related variables: A systematic review and meta-analysis of randomized controlled trials. Nutrition Bulletin. https://doi.org/10.1111/nbu.12693

5. https://www.sciencedirect.com/science/article/pii/S1476459824002063

6. Lyle, Nazmun, Hossain, Chowdhury Mobaswar, Pramanik, Krishna (2026) Therapeutic targeting of lipid metabolism in cancer: Mechanisms, pathways, and translational prospects. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2026.156507

7. Alhamzah, S.A., Gatar, O.M., Alruwaili, N.W. (2023) Effects of ketogenic diet on oxidative stress and cancer: A literature review. Advances in Cancer Biology - Metastasis. https://doi.org/10.1016/j.adcanc.2023.100093

8. Neha, Chaudhary, R. (2024) Ketogenic diet as a treatment and prevention strategy for cancer: A therapeutic alternative. Nutrition. https://doi.org/10.1016/j.nut.2024.112427

9. Allen, B.G., Bhatia, S.K., Anderson, C.M., (...), Fath, M.A. (2014) Ketogenic diets as an adjuvant cancer therapy: History and potential mechanism. Redox Biology. https://doi.org/10.1016/j.redox.2014.08.002

10. Khodabakhshi Fard, A., Akbari, M.E., Mirzaei, H.R., (...), Davoodi, S.H. (2020) Feasibility, Safety, and Beneficial Effects of MCT-Based Ketogenic Diet for Breast Cancer Treatment: A Randomized Controlled Trial Study. Nutrition and Cancer. https://doi.org/10.1080/01635581.2019.1650942

11. Klement, R.J., Weigel, M.M., Sweeney, R.A. (2021) A ketogenic diet consumed during radiotherapy improves several aspects of quality of life and metabolic health in women with breast cancer. Clinical Nutrition. https://doi.org/10.1016/j.clnu.2021.01.023

12. Klement, R.J., Meyer, D., Kanzler, S., Sweeney, R.A. (2022) Ketogenic diets consumed during radio-chemotherapy have beneficial effects on quality of life and metabolic health in patients with rectal cancer. European Journal of Nutrition. https://doi.org/10.1007/s00394-021-02615-y

13. Tan-Shalaby, J.L., Carrick, J., Edinger, K., (...), Shah, R.B. (2016) Modified Atkins diet in advanced malignancies - Final results of a safety and feasibility trial within the Veterans Affairs Pittsburgh Healthcare System. Nutrition and Metabolism. https://doi.org/10.1186/s12986-016-0113-y

14. Klement, R.J. (2017) Beneficial effects of ketogenic diets for cancer patients: a realist review with focus on evidence and confirmation. Medical Oncology. https://doi.org/10.1007/s12032-017-0991-5

15. Sremanakova, J., Sowerbutts, A.M., Burden, S. (2018) A systematic review of the use of ketogenic diets in adult patients with cancer. Journal of Human Nutrition and Dietetics. https://doi.org/10.1111/jhn.12587

16. Buga, A., Harper, D.G., Sapper, T.N., (...), Volek, J.S. (2024) Feasibility and metabolic outcomes of a well-formulated ketogenic diet as an adjuvant therapeutic intervention for women with stage IV metastatic breast cancer: The Keto-CARE trial. PLoS ONE. https://doi.org/10.1371/journal.pone.0296523

17. Augustus, E., Granderson, I., Rocke, K.D. (2021) The Impact of a Ketogenic Dietary Intervention on the Quality of Life of Stage II and III Cancer Patients: A Randomized Controlled Trial in the Caribbean. Nutrition and Cancer. https://doi.org/10.1080/01635581.2020.1803930

18. Klement, R.J., Sweeney, R.A. (2026) Survival outcomes of rectal and head and neck cancer patients receiving radio(chemo)therapy with a ketogenic diet. A post-hoc analysis from the KETOCOMP trial. Strahlentherapie und Onkologie.https://doi.org/10.1007/s00066-025-02499-5

19. Amaral, L.J., Gresham, G., Kim, S., (...), Hu, J. (2025) A phase 1 safety and feasibility trial of a ketogenic diet plus standard of care for patients with recently diagnosed glioblastoma. Scientific Reports. https://doi.org/10.1038/s41598-025-06675-6

20. Yang, Y.-F., Mattamel, P.B., Joseph, T., (...), Ming, W.-K. (2021) Efficacy of low-carbohydrate ketogenic diet as an adjuvant cancer therapy: A systematic review and meta-analysis of randomized controlled trials. Nutrients. https://doi.org/10.3390/nu13051388

21. AlMutairi, H., Mccullough, F., Siddiqui, K., (...), Dandapani, M. (2025) Safety, Feasibility, and Effectiveness of Ketogenic Diet in Pediatric Patients With Brain Tumors: A Systematic Review. Journal of Nutrition and Metabolism. https://doi.org/10.1155/jnme/7935879

22. Al-Taie, A., Elmasri, J. (2025) Prospects of the therapeutic approaches of ketogenic diet on the clinical outcomes of cancer: A scoping review. Bulletin du Cancer. https://doi.org/10.1016/j.bulcan.2025.05.012

23. Valerio, J., Borro, M., Proietti, E., (...), Alvarez-Pinzon, A.M. (2024) Systematic Review and Clinical Insights: The Role of the Ketogenic Diet in Managing Glioblastoma in Cancer Neuroscience. Journal of Personalized Medicine. https://doi.org/10.3390/jpm14090929

24. Li, R., Huang, Q., Ye, C., (...), Wang, Y. (2022) Bibliometric and visual analysis in the field of ketogenic diet on cancer from 2012 to 2021. Frontiers in Nutrition. https://doi.org/10.3389/fnut.2022.1060436

25. Khodabakhshi Fard, A., Akbari, M.E., Mirzaei, H.R., (...), Davoodi, S.H. (2021) Effects of Ketogenic metabolic therapy on patients with breast cancer: A randomized controlled clinical trial. Clinical Nutrition. https://doi.org/10.1016/j.clnu.2020.06.028

26. Persiani, M., Dallolio, L., Masini, A., (...), Sacchetti, R. (2026) Ketogenic Diet in the Treatment of Malignant Gliomas: A Systematic Review. Nutrients. https://doi.org/10.3390/nu18132166

27. Klement, R.J., Schäfer, G., Sweeney, R.A. (2020) A ketogenic diet exerts beneficial effects on body composition of cancer patients during radiotherapy: An interim analysis of the KETOCOMP study. Journal of Traditional and Complementary Medicine. https://doi.org/10.1016/j.jtcme.2019.03.007

28. https://www.sciencedirect.com/science/article/pii/S2072669426019785

For patients and families facing cancer, hope and careful questions belong together. Fenbendazole—a medicine used to treat parasitic worms in animals—has attracted attention because of laboratory findings and personal accounts of recovery. Those findings give researchers questions worth investigating. They do not yet establish that fenbendazole treats cancer safely or effectively in people.

The most hopeful way to tell this story is to neither promise a breakthrough nor dismiss curiosity. It is to explain what scientists have observed, listen respectfully to patients’ experiences, and be clear about what remains unknown.

Why researchers are interested

The scientific interest in fenbendazole is not based solely on social media. In a study published in Scientific Reports, researchers found that it interfered with tubulin, a building block of the microscopic structures involved in cell division. In laboratory cancer cells, it also affected glucose uptake and proteins involved in using that fuel. In mice carrying transplanted human tumors, oral treatment inhibited tumor growth.

These results suggest several possible ways the drug might affect cancer biology. But the phrase “human cancer cells” needs careful reading: cells grown in a laboratory, or transplanted into mice, are not the same as patients receiving treatment. The findings support investigation, not a conclusion that taking fenbendazole will produce the same effects in a person.

Other experiments have explored different cancers. Researchers studying colorectal cancer cells resistant to the chemotherapy drug fluorouracil found that fenbendazole triggered programmed cell death and interrupted the cell-division cycle. This is a reason to investigate drug-resistant cancer biology—not evidence that fenbendazole overcomes chemotherapy resistance in patients.

A separate breast-cancer laboratory study found that triple-negative breast cancer cells were more vulnerable to fenbendazole-induced oxidative stress than another breast cancer cell line. The researchers also observed different effects in normal breast epithelial cells. Such differences are scientifically interesting because they may help identify which biological settings deserve further study, but this experiment did not test treatment in people.

The laboratory picture is not uniformly positive. In another study, fenbendazole damaged mouse mammary tumor cells in culture but did not slow tumor growth in living mice or improve radiation's antitumor effects. Including this result matters: a promising effect in a dish does not guarantee a useful medicine.

Joe Tippens: a hopeful story, with an important unanswered question

Joe Tippens is among the best-known people to credit fenbendazole with his recovery. In news coverage, he described having small-cell lung cancer that had spread widely and said that fenbendazole helped rid him of cancer. His account offers a powerful personal story of hope.

However, the same coverage reported that he also received an experimental cancer drug and took supplements. The American Cancer Society explains that the widely shared lung-cancer story involved participation in an immunotherapy clinical study at the same time as fenbendazole use.

That overlap prevents a reliable conclusion about what fenbendazole contributed, if anything. A recovery can be meaningful and encouraging without proving the explanation attached to it. Tippens’ story can motivate a research question; it cannot answer that question on its own.

What about other reports of human use?

The American Cancer Society notes that people with breast, prostate, skin, and other cancers have reported becoming “cancer-free” after taking fenbendazole. In most cases, however, they also received standard cancer treatments. These are reports of use and outcomes—not proof that fenbendazole caused the outcomes.

A published case-report abstract also describes regression of diffuse large B-cell lymphoma in a patient who declined chemotherapy and took fenbendazole. That observation is worth distinguishing from an online testimonial, but it remains an isolated report, not a controlled test.

Publication alone does not guarantee dependable evidence. A case series describing fenbendazole self-administration in people with breast cancer, prostate cancer, and melanoma is marked as retracted.

Protecting hope means taking safety seriously

Fenbendazole is not FDA-approved for any human use, and its safety and effectiveness as a cancer treatment have not been established. Experience treating parasites in animals does not provide the missing evidence in humans.

The American Society of Clinical Oncology advises against using fenbendazole either as a cancer treatment or as an addition to established treatment outside a well-designed clinical trial, citing the lack of established benefit and potential harms.

For patients and families, asking about fenbendazole should be a conversation, not a confrontation. Useful questions include: What evidence applies to this particular cancer? Could an unproven product interfere with current care? Are there appropriate clinical trials of repurposed medicines? Anyone already taking fenbendazole should tell their oncology team rather than stop or delay prescribed cancer treatment to follow an online account.

A hopeful next chapter is possible—but it must be earned

Fenbendazole has produced biological effects worth investigating in laboratory cancer models. It has also become part of personal recovery stories that deserve respectful, careful discussion. What is missing is robust clinical evidence showing whether it improves outcomes for people with cancer and whether any benefit outweighs its risks.

We support rigorous research, ask informed questions, and keep patients’ lives—not the popularity of a particular drug—at the center of the story.

• What to Know About Fenbendazole | American Cancer Society, 2025.

• Dogra et al., 2018. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Scientific Reports.

• Park et al., 2022. Anti-cancer effects of fenbendazole on 5-fluorouracil-resistant colorectal cancer cells. Korean Journal of Physiology and Pharmacology.

• Semkova et al., 2023. Redox-mediated Anticancer Activity of Anti-parasitic Drug Fenbendazole in Triple-negative Breast Cancer Cells. Anticancer Research.

• Duan et al., 2013. Fenbendazole as a Potential Anticancer Drug. Anticancer Research.

• Kertscher, 2023. No proof that the dog deworming drug fenbendazole can cure human cancer – PolitiFact.

• Abughanimeh et al., 2020. Fenbendazole as a Treatment for Diffuse Large B-CellLymphoma.

• William Makis, 2025. Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients.

• Yamaguchi et al., 2021. Drug-Induced Liver Injury in a Patient with Nonsmall Cell Lung Cancer after the Self-Administration of Fenbendazole Based on Social Media Information. Case Reports in Oncology.

• ASCO Clinical Notice: Recommending Against Ivermectin and Fenbendazole for Cancer Treatment, Outside of Clinical Trials | ASCO Connection.

Preclinical studies demonstrate that the deworming medication fenbendazole exhibits promising anticancer properties across a wide variety of laboratory and animal tumor models. The primary mechanism driving this activity is microtubule and tubulin disruption, which consistently triggers subsequent cellular events such as programmed cell death, metabolic suppression, and cell cycle arrest. However, the overall evidence remains heterogeneous, as strong in vitro results do not always translate into successful animal outcomes. To overcome the drug's inherent limitations, researchers are developing advanced nanocarrier formulations to improve absorption, solubility, and therapeutic delivery.

Fenbendazole has substantial preclinical cancer research, mostly in cell culture and mouse/xenograft models, with recurring signals for microtubule disruption, p53/p21 signaling, ROS induction, glucose-uptake inhibition, and apoptosis; however, not every model is positive, and one lymphoma mouse study found no in vivo antitumor effect despite in vitro activity.

What these studies collectively show

• Most consistent mechanism: microtubule/tubulin disruption is the central recurring theme across fenbendazole cancer studies.

• Frequent downstream effects: G2/M arrest, apoptosis, ROS production, p53/p21 activation, and metabolic inhibition recur across multiple models.

• Formulation matters: several studies focus on improving solubility, absorption, and delivery with micelles, PLGA nanoparticles, cyclodextrin complexes, and other carriers because native fenbendazole is poorly soluble.

• Evidence is mixed in vivo: while xenograft and orthotopic models show antitumor activity in some settings, at least one mouse lymphoma model showed no in vivo benefit despite in vitro cytotoxicity.

Bottom line: the preclinical fenbendazole literature is real and fairly broad, but it is heterogeneous—strongest for cell-line cytotoxicity and mechanism studies, more variable for animal efficacy, and still limited by poor solubility and inconsistent in vivo translation.

References

1. Dogra, N., Kumar, A., Mukhopadhyay, T. (2018) Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Scientific Reports. https://doi.org/10.1038/s41598-018-30158-6

2. Dogra, N., Mukhopadhyay, T. (2012) Impairment of the ubiquitin-proteasome pathway by methyl N-(6-phenylsulfanyl-1H-benzimidazol-2-yl)carbamate leads to a potent cytotoxic effect in tumor cells: A novel antiproliferative agent with a potential therapeutic implication. Journal of Biological Chemistry. https://doi.org/10.1074/jbc.M111.324228

3. Park, D. (2022) Fenbendazole Suppresses Growth and Induces Apoptosis of Actively Growing H4IIE Hepatocellular Carcinoma Cells via p21-Mediated Cell-Cycle Arrest. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.b21-00697

4. Jung, H., Kim, S.-Y., Joo, H.-G. (2023) Fenbendazole Exhibits Differential Anticancer Effects In Vitro and In Vivo in Models of Mouse Lymphoma. Current Issues in Molecular Biology. https://doi.org/10.3390/cimb45110560

5. Peng, Y., Pan, J., Ou, F., (...), Yu, L. (2022) Fenbendazole and its synthetic analog interfere with HeLa cells’ proliferation and energy metabolism via inducing oxidative stress and modulating MEK3/6-p38-MAPK pathway. Chemico-Biological Interactions. https://doi.org/10.1016/j.cbi.2022.109983

6. Han, Y., Joo, H.-G. (2020) Involvement of reactive oxygen species in the anti-cancer activity of fenbendazole, a benzimidazole anthelmintic. Korean Journal of Veterinary Research. https://doi.org/10.14405/kjvr.2020.60.2.79

7. Jung, H., Lee, Y.-J., Joo, H.-G. (2023) Differential cytotoxic effects of fenbendazole on mouse lymphoma EL-4 cells and spleen cells. Korean Journal of Veterinary Research. https://doi.org/10.14405/kjvr.20220040

8. Mrkvová, Z., Uldrijan, S., Pombinho, A., (...), Slaninová, I. (2019) Benzimidazoles downregulate MDM2 and MDMX and activate p53 in MDMX overexpressing tumor cells. Molecules. https://doi.org/10.3390/molecules24112152

9. Makis, W., Baghli, I., Martinez, P. (2025) Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients. Case Reports in Oncology. https://doi.org/10.1159/000546362

10. Vlachou, I., Parsonidis, P., Mamagkaki, A., (...), Papasotiriou, I. (2022) Teaching an old dog new tricks: The case of Fenbendazole. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2022.100601

11. Yamaguchi, T., Shimizu, J., Oya, Y., (...), Hida, T. (2021) Drug-Induced Liver Injury in a Patient with Nonsmall Cell Lung Cancer after the Self-Administration of Fenbendazole Based on Social Media Information. Case Reports in Oncology. https://doi.org/10.1159/000516276

12. Chang, C.-S., Ryu, J.-Y., Choi, J.-K., (...), Lee, J.-W. (2023) Anti-cancer effect of fenbendazole-incorporated PLGA nanoparticles in ovarian cancer. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2023.34.e58

13. Shin, Y.B., Choi, J.-Y., Shin, D.H., Lee, J.-W. (2023) Anticancer Evaluation of Methoxy Poly(Ethylene Glycol)-b-Poly(Caprolactone) Polymeric Micelles Encapsulating Fenbendazole and Rapamycin in Ovarian Cancer. International Journal of Nanomedicine. https://doi.org/10.2147/IJN.S394712

14. Shin, H.J., Jo, M.J., Jin, I.S., (...), Shin, D.H. (2021) Optimization and pharmacokinetic evaluation of synergistic fenbendazole and rapamycin co-encapsulated in methoxy poly(Ethylene glycol)-b-poly(caprolactone) polymeric micelles. International Journal of Nanomedicine. https://doi.org/10.2147/IJN.S315782

15. Rana, N., Deval, Singh, H., (...), Sharma, S. (2026) Current landscape and recent developments of PI3K/AKT/mTOR targeted inhibitors for breast carcinoma. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2025.109430

16. Ding, Y., Zhang, Z., Ding, C., (...), Xu, Z. (2024) Preparation and evaluation of fenbendazole methyl-β-cyclodextrin inclusion complexes. BMC Veterinary Research. https://doi.org/10.1186/s12917-024-04056-1

17. Jin, I.S., Jo, M.J., Park, C.-W., (...), Shin, D.H. (2020) Physicochemical, pharmacokinetic, and toxicity evaluation of soluplus® polymeric micelles encapsulating fenbendazole. Pharmaceutics. https://doi.org/10.3390/pharmaceutics12101000

18. Karimi, A., Barea, P., Benito-Román, Ó., (...), Lyons, J.G. (2025) Investigation of Fenbendazole Solubility Using Particle Size Reduction Methods in the Presence of Soluplus®. Pharmaceutics. https://doi.org/10.3390/pharmaceutics17091163

19. Duan, Q., Liu, Y., Rockwell, S. (2013) Fenbendazole as a potential anticancer drug. Anticancer Research. https://www.scopus.com/pages/publications/84875878997

20. Duan, Q., Liu, Y., Booth, C.J., Rockwell, S. (2012) Use of fenbendazole-containing therapeutic diets for mice in experimental cancer therapy studies. Journal of the American Association for Laboratory Animal Science. https://www.scopus.com/pages/publications/84859149741

Preclinical research on repurposed antiparasitic agents—including benzimidazoles (fenbendazole, mebendazole, albendazole, flubendazole), ivermectin, and niclosamide—demonstrates broad cytotoxic, metabolic, and anti-metastatic activity across cell culture (in vitro) and animal xenograft (in vivo) cancer models.

1. Core Mechanisms Identified in Preclinical Models

• Microtubule Disruption & Cell Cycle Arrest: Benzimidazoles bind specifically to β-tubulin at the colchicine-binding site, inhibiting tubulin polymerization, causing G2/M cell cycle arrest, and triggering mitotic catastrophe across lung, cervical, melanoma, hepatocellular, and brain cancer models.

• Metabolic Starvation (Warburg Effect Suppression): Fenbendazole and mebendazole downregulate key glucose transporters (GLUT1 and GLUT4) and hexokinase II (HKII), blocking aerobic glycolysis and severely depleting cellular ATP in glucose-dependent tumors.

• Reactivation of Tumor Suppressor Pathways (p53 / p21 Axis): Benzimidazoles downregulate MDM2 and MDMX (the negative regulators of p53), driving p53 stabilization and elevating p21 to induce cell-cycle arrest and apoptosis even in MDMX-overexpressing or p53-mutant lines.

• ROS Generation, ER Stress & Non-Apoptotic Cell Death: Fenbendazole induces intracellular reactive oxygen species (ROS) accumulation, leading to loss of mitochondrial membrane potential, proteasomal dysfunction, endoplasmic reticulum (ER) stress, caspase activation, gasdermin-mediated pyroptosis, and lipid peroxidation (ferroptosis).

• Multi-Pathway Cascades (Ivermectin & Niclosamide):

  • Ivermectin suppresses master oncogenic drivers, including Akt/mTOR, Wnt/β-catenin, PAK1, YAP1, and KPNB1, while EGFR inhibition downregulates P-glycoprotein (P-gp) efflux pumps and drives P2X7-mediated immunogenic cell death.

  • Niclosamide acts as a potent mitochondrial uncoupling protonophore while simultaneously suppressing Wnt/β-catenin, STAT3, Notch, and mTORC1 signaling.

2. Cancer Subtypes Investigated in Preclinical Studies

• Non-Small Cell Lung Cancer (NSCLC): Fenbendazole and mebendazole inhibit proteasome function, induce ER stress-dependent apoptosis, and significantly suppress tumor growth in human xenograft mouse models.

• Ovarian Cancer & Chemoresistance: Fenbendazole and ivermectin suppress cell proliferation in both chemosensitive and chemoresistant ovarian cancer cell lines, restoring sensitivity to agents like paclitaxel or pitavastatin.

• Primary Brain Tumors (GBM, Medulloblastoma, DIPG): Mebendazole shows strong therapeutic efficacy in animal models of glioblastoma and medulloblastoma because it is highly lipophilic and can cross the blood-brain barrier.

• Hepatocellular Carcinoma & Cervical Cancer: Fenbendazole selectively halts actively dividing cells via p21-mediated arrest and activates the MEK3/6-p38-MAPK stress signaling pathway to block invasion and migration.

• Leukemia, Lymphoma & Melanoma: Albendazole, flubendazole, and fenbendazole induce mitochondrial depolarization, apoptosis, and loss of viability across hematologic and melanoma cell lines.

3. In Vitro vs. In Vivo Translation & Bioavailability Barriers

While in vitro cell-line destruction is consistently reported across studies, animal model outcomes reveal notable challenges and heterogeneity:

• Inconsistent In Vivo Translation: Strong cell-culture cytotoxicity does not always guarantee in vivo tumor control. For instance, in a mouse EL-4 lymphoma model, fenbendazole induced ROS, mitochondrial damage, and G2/M arrest in vitro but showed no significant anticancer effect in vivo.

• Poor Aqueous Solubility & Absorption: Native fenbendazole, mebendazole, and niclosamide are highly hydrophobic and poorly absorbed orally, making it difficult to achieve active cytotoxic concentrations in animal blood plasma or tumor tissues without specialized delivery methods.

• Nanocarriers & Delivery Optimization: To bridge this translation gap, preclinical researchers use advanced delivery platforms:

  • PLGA Nanoparticles: Encapsulating fenbendazole into PLGA nanocarriers optimizes intratumoral drug delivery and yields significantly improved antitumor efficacy in ovarian cancer xenografts and patient-derived xenograft (PDX) models.

  • Polymeric Micelles (mPEG-PCL & Soluplus®): Co-encapsulating fenbendazole with rapamycin in polymeric micelles produces potent synergistic tumor suppression by simultaneously blocking tubulin dynamics and mTOR survival pathways.

  • Cyclodextrin Inclusion Complexes: Methyl-β-cyclodextrin host-guest complexes dramatically elevate fenbendazole’s dissolution rate and bio-accessibility in biological fluids.

4. Preclinical Synergistic Combinations

• Ivermectin + Chemotherapy: Combining ivermectin with paclitaxel, gemcitabine, or sorafenib blocks drug-efflux pumps (P-gp downregulation) and enhances apoptotic sensitivity in resistant tumor models.

• Flubendazole + Cytotoxic Agents: Flubendazole synergistically enhances the cytotoxicity of 5-fluorouracil (5-FU), doxorubicin, vinblastine, and vincristine in breast cancer and leukemia lines.

Sources:

1. Peer-Reviewed Journal Article

• Armando, R. G., et al. (2020). Drug repositioning in oncology: Benzimidazole derivatives. International Journal of Oncology, 56(3), 651–684.

2. Online Evidence Guide (Fenbendazole and Ivermectin for Cancer: Real Stories, Science & Protocols (2025 Guide))

• OneDayMD Editorial Team. (2026, September). Fenbendazole and ivermectin for cancer: Real stories, science & protocols (2025 guide) (F. Yap, Med. Rev.). One Day MD’s Newsletter.

Because native fenbendazole is highly hydrophobic, poorly soluble in water, and has low oral bioavailability, high cell-line cytotoxicity often fails to translate into consistent in vivo antitumor performance in animal models.

To bridge this translation gap, researchers use advanced nanocarriers and inclusion complexes to dramatically increase drug solubility, prolong systemic circulation, and enhance intracellular delivery to tumor cells.

1. PLGA Nanoparticles (Poly(lactic-co-glycolic acid))

• Enhanced Solubilization & Uptake: Encapsulating fenbendazole inside biodegradable PLGA polymers overcomes solubility barriers and facilitates cellular internalization via endocytosis.

• Reversing Chemoresistance: In ovarian cancer models, PLGA-fenbendazole nanoparticles significantly decrease cell proliferation across both chemosensitive and chemoresistant cell lines.

• Superior In Vivo Tumor Control: Unlike free fenbendazole, PLGA nano-formulations deliver sustained intratumoral drug concentrations, yielding marked tumor suppression in ovarian cancer xenografts and patient-derived xenograft (PDX) models.

PLGA (poly(lactic-co-glycolic acid)) nanoparticles address fenbendazole's primary pharmacological limitations: poor aqueous solubility and poor oral absorption.

PLGA nanoparticles improve fenbendazole delivery and therapeutic performance through several key mechanisms:

• Overcoming Solubility & Absorption Barriers: Native fenbendazole struggles with poor systemic bioavailability in biological fluids. Encapsulating the drug in PLGA nanocarriers significantly improves its solubility, stability, and systemic delivery.

• Overcoming Drug Resistance: In preclinical ovarian cancer models, PLGA-encapsulated fenbendazole efficiently penetrates cancer cells, decreasing cell proliferation across both chemosensitive and chemoresistant tumor lines.

• Enhancing In Vivo Antitumor Efficacy: Native fenbendazole can yield inconsistent results in animal models because of poor absorption, but PLGA nanoparticle formulations optimize drug delivery to the tumor site, resulting in significantly improved antitumor efficacy in xenograft and patient-derived xenograft (PDX) models.

2. Polymeric Micelles (mPEG-PCL & Soluplus®)

• Amphiphilic Nanocarriers: Synthetic block-copolymer micelles—such as methoxy poly(ethylene glycol)-b-poly(caprolactone) (mPEG-PCL) and Soluplus®—entrap hydrophobic fenbendazole within a lipophilic core surrounded by a hydrophilic shell.

• Dual-Drug Combination & Synergism: Polymeric micelles enable co-encapsulation of fenbendazole alongside targeted agents like rapamycin. This dual-delivery strategy simultaneously blocks microtubule dynamics (fenbendazole) and inhibits mTOR survival pathways (rapamycin), producing potent synergistic antitumor effects in orthotopic ovarian cancer models.

• Improved Pharmacokinetics: Micellar encapsulation shields the drug from rapid hepatic clearance, increases systemic half-life, and optimizes tissue distribution while minimizing non-target toxicity.

3. Cyclodextrin Inclusion Complexes

• Host-Guest Entrapment: Cyclodextrins (such as methyl-\(\beta\)-cyclodextrin) form molecular inclusion complexes by entrapping fenbendazole’s hydrophobic ring structure within their central hydrophobic cavity while maintaining a hydrophilic exterior.

• Rapid Dissolution & Bio-accessibility: This non-covalent entrapment dramatically increases fenbendazole’s dissolution rate and aqueous solubility in biological fluids without altering its chemical scaffold or biological activity.

4. Impact on Apoptotic Efficacy

By ensuring sustained, high-level intracellular drug accumulation within tumor tissues, these advanced delivery systems amplify downstream apoptotic cascades:

• Sustained Microtubule Destabilization: Maintains prolonged \(\text{G}_2/\text{M}\) phase cell-cycle arrest.

• Elevated Oxidative Stress: Drives intracellular reactive oxygen species (ROS) accumulation, leading to loss of mitochondrial membrane potential.

• Tumor Suppressor Reactivation: Downregulates MDM2/MDMX to reactivate the p53/p21 pathway, triggering robust intrinsic apoptosis and cell death even in chemoresistant tumor populations.

1. Primary Synthesis Source Citation (APA 7th Edition)

• Preclinical Research on Fenbendazole Treating Cancer. (2026). 10-14-article.odt [Synthesis Review & Meta-Analysis Document].

2. Primary Studies Synthesized in the Source

A. Microtubule Disruption & Apoptotic Signaling

• Dogra, N., Kumar, A., & Mukhopadhyay, T. (2018). Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Scientific Reports, 8(1), Article 11926. https://doi.org/10.1038/s41598-018-30158-6

• Dogra, N., & Mukhopadhyay, T. (2012). Impairment of the ubiquitin-proteasome pathway by methyl N-(6-phenylsulfanyl-1H-benzimidazol-2-yl)carbamate leads to a potent cytotoxic effect in tumor cells. Journal of Biological Chemistry, 287(38), 32422–32435. https://doi.org/10.1074/jbc.M111.324228

• Park, D. (2022). Fenbendazole suppresses growth and induces apoptosis of actively growing H4IIE hepatocellular carcinoma cells via p21-mediated cell-cycle arrest. Biological and Pharmaceutical Bulletin, 45(5), 697–703. https://doi.org/10.1248/bpb.b21-00697

• Peng, Y., Pan, J., Ou, F., & Yu, L. (2022). Fenbendazole and its synthetic analog interfere with HeLa cells’ proliferation and energy metabolism via inducing oxidative stress and modulating MEK3/6-p38-MAPK pathway. Chemico-Biological Interactions, 368, Article 109983. https://doi.org/10.1016/j.cbi.2022.109983

B. Advanced Nanocarrier Delivery Systems & Formulations

• Chang, C.-S., Ryu, J.-Y., Choi, J.-K., & Lee, J.-W. (2023). Anti-cancer effect of fenbendazole-incorporated PLGA nanoparticles in ovarian cancer. Journal of Gynecologic Oncology, 34(5), Article e58. https://doi.org/10.3802/jgo.2023.34.e58

• Ding, Y., Zhang, Z., Ding, C., & Xu, Z. (2024). Preparation and evaluation of fenbendazole methyl-β-cyclodextrin inclusion complexes. BMC Veterinary Research, 20(1), Article 40561. https://doi.org/10.1186/s12917-024-04056-1

• Jin, I. S., Jo, M. J., Park, C.-W., & Shin, D. H. (2020). Physicochemical, pharmacokinetic, and toxicity evaluation of Soluplus® polymeric micelles encapsulating fenbendazole. Pharmaceutics, 12(10), Article 1000. https://doi.org/10.3390/pharmaceutics12101000

• Shin, Y. B., Choi, J.-Y., Shin, D. H., & Lee, J.-W. (2023). Anticancer evaluation of methoxy poly(ethylene glycol)-b-poly(caprolactone) polymeric micelles encapsulating fenbendazole and rapamycin in ovarian cancer. International Journal of Nanomedicine, 18, 4821–4835. https://doi.org/10.2147/IJN.S394712

C. In Vivo Efficacy & Model Discrepancies

• Duan, Q., Liu, Y., & Rockwell, S. (2013). Fenbendazole as a potential anticancer drug. Anticancer Research, 33(2), 355–362.

• Jung, H., Kim, S.-Y., & Joo, H.-G. (2023). Fenbendazole exhibits differential anticancer effects in vitro and in vivo in models of mouse lymphoma. Current Issues in Molecular Biology, 45(11), 8820–8831. https://doi.org/10.3390/cimb45110560